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1. List of Abbreviations 
 
ACTB – human β-actin 
AF – AlexaFluor 
AFP – alpha-fetoprotein 
ALCAM/CD166 - activated leukocyte cell adhesion molecule 
APC - allophycocyanin 
bFGF – basic fibroblast growth factor 
βIII-Tub – beta-III tubulin 
BMP4 - bone morphogenetic protein 4 
CAPG – capping protein gelsolin-like 
CD – cluster of differentiation 
C-KIT/CD117 - tyrosine kinase Kit 
CM – cardiomyocyte 
CMSC – cardiomyocyte supporting cell 
CMV - cytomegalovirus 
CPC – cardiac progenitor cells 
cTnI – cardiac troponin I  
D - day 
DM – differentiation medium 
DMEM – Dulbecco’s Modified Eagle’s Medium 
EB – embryoid body 
EMT – epithelial-to-mesenchymal transition 
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END-2 - mouse visceral endoderm-like cells 
END2-CM – END-2 conditioned medium 
FACS - fluorescence activated cell sorting 
FBS – fetal bovine serum 
FITC - fluorescein isothiocyanate 
GFP – green fluorescent protein 
hESC – human embryonic stem cell 
hiPSC – human induced pluripotent stem cell 
hPSC – human pluripotent stem cell 
ISL1 - insulin gene enhancer protein 
KDR/VEGF-R - vascular endothelial growth factor receptor 2 
MEF – mouse embryonic fibroblast 
mESC – mouse embryonic stem cell 
MTG – monothioglycerol 
PAX6 - paired box 6 
PDGFRA - platelet-derived growth factor receptor 
PE - phycoerythrin 
PECAM-1 – platelet endothelial cell adhesion molecule-1 
PGK - phosphoglycerate kinase 
PI - propidium iodide 
QPCR - real-time quantitative PCR 
RCM – ReproCardio Medium 
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rEBs – reaggregated embryoid bodies 
SIRPA/CD47 - signal regulatory protein α 
SMA – alpha-smooth muscle actin 
SSEA4 - stage-specific embryonic antigen-4 
TBX5 - T-Box Protein 5 
TMRM - tetramethylrhodamine methyl ester perchlorate  
TNNT2 - troponin T type 2 
UbC - ubiquitinC  
VCAM1/CD106 - vascular cell adhesion molecule 1   
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2. Introduction 
Stem cells are capable of renewing themselves through cell division for unlimited 
times and divide asymmetrically, generating two different daughter cells. Under certain 
physiological or experimental conditions, stem cells can be induced to become tissue-
specific cells with special functions through differentiation. Stem cells can have different 
potentials (e.g. toti-, pluri- or multipotency), limiting the number of tissue types that can 
be differentiated from them.  
Features of pluripotency include the potential of unlimited cell growth and self-
renewal, as well as the capacity to generate all cell types of the body. However, 
pluripotent cells are restricted in their potential compared to totipotent stem cells, since 
human pluripotent stem cells (hPSCs) cannot give rise to cells of the extra-embryonic 
tissues (amnion, chorion, yolk sac and the allantois). Multipotent stem cells have even 
lower potential and only give rise to tissue-specific cells. Therefore multipotent stem cells 
are often termed as multipotent progenitor cells of certain developmental lineages. 
This dissertation will focus on hPSCs and their in vitro differentiation capabilities, 
with a specific focus on the cardiac lineage to provide a method for identifying and 
isolating cell types at different stages of cardiac commitment. 
 
2.1. Human pluripotent stem cells  
2.1.1 Generation of human pluripotent stem cells 
The derivation of mouse pluripotent stem cell lines from blastocyst-stage embryos 
revolutionized biological research through allowing generation of knock-out animal 
models (2007 Nobel Prize) and opening new possibilities in studying early developmental 
events. The much awaited next step, the establishment of the first human embryonic stem 
cell (hESC) line was reported by Thomson et al. seventeen years later, in 19981. The 
generation of hESC lines proved to be as revolutionary as the establishment of mouse 
ESC lines earlier, providing an excellent platform for human developmental studies and 
toxicological screenings, as well as the possibility of regenerative therapeutic 
applications. 
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Human ESC lines are usually derived from the inner cell mass of blastocyst stage 
embryos (see Figure 1). Unfortunately, ethical concerns regarding the use of in vitro-
fertilized human embryos for research purposes strongly hinder the application of hESCs 
in basic research, drug development and medical therapy, even though the embryos are 
otherwise supposed to be destroyed. In addition to the ethical concerns, several other 
drawbacks exist. One of these is the potential immunological incompatibility that might 
limit the use of hESC-derived cells for regenerative purposes2. However, immunological 
problems may be prevented by hESC-banking3, 4 or transplantation of encapsulated 
hESC-derivatives secreting the necessary factors to compensate for deficits5.  
 
 
Figure 1. Methods for the generation and differentiation of human pluripotent 
stem cell lines. The image is taken from Szebényi et al.6  
 
In 2006, another milestone of stem cell research was reached when induced 
pluripotent stem cells (iPSC) were generated from mouse fibroblast cultures by forced 
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expression of four transcription factors (Oct3/4, Sox2, Klf4 and c-Myc)7. This study was 
immediately followed by numerous others, documenting the generation of human induced 
pluripotent stem cells (hiPSCs) with viral or non-viral delivery of the reprogramming 
factors8 (see Figure 1). The discovery that mature cells can be reprogrammed to become 
pluripotent was honoured by the 2012 Nobel Prize. 
By now, hundreds of hPSC lines exist and many of them are available from tissue 
banks, while cell-line specific information has been collected and made accessible in 
Stem Cell Registries (reviewed by Borstlap et al.9). 
 
2.1.2 Culture and characterization of human pluripotent stem cells  
 Human iPSCs are similar to hESCs regarding their morphological and 
proliferative characteristics, as well as cell surface marker and gene expression profiles or 
differentiation potential. Small colonies of hESCs and hiPSCs are usually maintained on 
mitotically inactivated feeder cells (mouse or human10, 11), or on extracellular matrix-
coated surfaces (e.g. Matrigel12, Laminin13, 14 or Vitronectin15, 16) (see Figure 1). Feeder 
cells secrete necessary factors for maintaining the pluripotent state, therefore a special 
type of medium is needed for culturing hPSCs on extracellular matrix-coated surfaces 
(e.g. mTeSR, MEF conditioned medium or Essential 8 medium), to compensate for the 
absence of the feeder layer. 
 Several widely accepted markers for testing the undifferentiated (pluripotent) 
state of hPSC  cultures exist, including alkaline phosphatase activity, expression of cell 
surface molecules (SSEA3, SSEA4, TRA1-60 TRA1-81, E-Cadherin), and transcription 
factors e.g. Nanog, Oct3/4 and Sox2 17. During long-term cell culture chromosomal 
abnormalities are frequently acquired, therefore methods to monitor and suppress 
abnormal karyotype acquisition are crucial18-21. The problem of large-scale production of 
high quality hPSCs has been also addressed, resulting in different solutions such as 
robotic systems22 or 3D culture expansion in stirring suspension bioreactors23-26.  
 Under adequate conditions hPSCs differentiate spontaneously to cells of all three 
primitive germ layers (endoderm, ectoderm and mesoderm)27. In vivo this leads to the 
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development of benign tumours (teratomas), containing a random mixture of partially 
developed tissues. In vitro hPSCs can spontaneously differentiate into specific cell types, 
including neurons, cardiomyocytes, epithelial and mesenchymal cells, although the output 
of each differentiation may vary depending on lot-to-lot variation of the reagents, e.g. 
foetal bovine serum (FBS), used to provide necessary differentiation signals. Therefore, 
several well-defined and reproducible methods for hPSC differentiation have been 
developed, allowing generation of cell populations by applying defined growth factors or 
chemical inducers instead of FBS or co-culture of hESCs with cells capable of lineage 
specific induction (more to this topic in Chapter 1.4)28. By using these methods, 
designated collectively as directed differentiation, clinically relevant cells types could be 
generated, including neural tissues29, 30, cardiomyocytes31, insulin producing islet cells32, 
33
, and various blood cells34. However, it is important to emphasize, that in vitro 
developing cells usually reach a maturation status resembling rather the embryonic than 
the adult phenotype, therefore some studies aimed to develop techniques for maturation 
of specific cell types35-38. 
 There is one key point where hiPSCs and hESCs may differ from each other, and 
that is the epigenetic memory of hiPSCs inherited from the reprogrammed somatic cells 
and gained through the reprogramming itself (reprogramming-specific epigenetic 
signature), eventually keeping away iPSCs from ground state pluripotency39-41. Even 
functional differences among hESC and hiPSC-derivatives have been reported42, 43 . 
Therefore the existence of iPSC technology does not mean that there is no need for 
hESCs anymore - actually the use of hiPSCs makes hESCs indispensable as controls for 
hiPSCs-based models. A more technical issue is that development of new methods 
(genetic or non-genetic), allowing the isolation of a specific cell type, should be carried 
out on several types of hPSCs, since these methods have to be equally valid for hESCs 
and hiPSCs.   
 Still, hPSCs and their derivatives provide an excellent basis for studying early 
events of human development and for the establishment of human cellular drug screening 
model systems. New medical regenerative therapies based on various hESCs are already 
in clinical trials44.  
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2.1.3 Application of human pluripotent stem cells and their derivatives 
A major point where hiPSCs and hESCs are different is that the generation of 
hiPSCs does not require the use of human embryos, and therefore ethical concerns 
attenuate. An additional benefit of hiPSCs over hESCs is that the iPSC technology can 
provide patient- and disease-specific pluripotent stem cells and derivatives, allowing 
personalized in vitro disease modelling, drug screening, and even cellular replacement 
therapies without immunological problems.  
 The potential of hiPSCs in therapeutic approaches was examined in several 
proof-of-concept studies, e.g. in models of sickle cell anaemia45, Fanconi anaemia46 or 
Parkinson’s disease47. In the case of the sickle cell anaemia model it was demonstrated 
that patient-derived hiPSCs can be corrected by targeted gene modification, while in the 
case of Fanconi anaemia the authors corrected patient-derived somatic cells before 
reprogramming and generated phenotypically normal haematopoietic progenitors of the 
myeloid and erythroid lineages from the corrected hiPSCs, thereby providing evidence for 
the potential of the iPSC technology in future therapeutic applications.  
 Disease-specific hPSC derivatives can also be used in screening applications to 
find drug candidate molecules allowing the rescue of the disease phenotype. In the case of 
hiPSCs derived from a patient with familial dysautonomia the authors revealed not only 
disease specific defects in neurogenesis but also found a compound that positively 
affected the otherwise defective migration of neural crest precursors48.  
Besides hiPSC-based disease models, disease-specific hESC lines also exist and 
are mostly derived from embryos diagnosed to carry mutations causing human diseases 
in Preimplantation Genetic Diagnosis49. Several hESC lines have been developed 
providing in vitro models for adrenoleukodystrophy, Duchenne and Becker muscular 
dystrophy, Fanconi anaemia, complementation group A, fragile-X syndrome, 
Huntington disease, Marfan syndrome, myotonic dystrophy, neurofibromatosis type I 
and thalassaemia50. 
 Another application of hPSCs is to provide human cardiomyocytes (CMs) for the 
drug development process, in order to test for cardiac side effects of drugs.  These effects 
are the most common causes of withdrawal of already approved drugs from the market, 
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and result from the species differences (e.g. in ion channel drug sensitivities) between 
humans and the animal models used for preclinical toxicity studies 51. In addition, cardiac 
disease-specific human CMs can be used in screening applications, either aiming to find 
drug candidate molecules allowing to rescue the disease phenotype, or to detect disease-
specific cardiotoxic side effects of any type of drugs. 
 Several hiPSC lines were derived from patients with cardiac channelopathies, 
such as the Long-QT syndrome type 152, Long-QT syndrome 253 and Timothy 
syndrome54, while other congenital diseases affecting the heart such as the 
catecholaminergic polymorphic ventricular tachycardia55, the arrhythmogenic right 
ventricular dysplasia/cardiomyopathy56, the glycogen storage disease type II (Pompe) 
disease57 or the LEOPARD syndrome58 could also be modelled by hiPSC-derived CMs. 
A more detailed review of existing cardiac disease-specific iPSC lines can be found in the 
attached book chapter by Szebényi et al., “Human Stem-Cell-Derived Cardiomyocytes in 
Drug Discovery and Toxicity Testing” (attached to the dissertation).  
    
2.2. Generation of cardiomyocytes from human pluripotent stem cells 
Human PSCs provide an unlimited source for differentiated cells through their 
unlimited self-renewal ability. However, directed differentiation protocols are needed to 
allow the enrichment of the cell type of particular interest, and to render its production 
economical, enabling the use of hPSC-derivatives in large-scale applications such as 
drug screening or therapeutic approaches.  
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Figure 2. Differentiation methods to generate cardiomyocytes from human 
pluripotent stem cells. 
 
Figure 2 shows various methods applied for cardiac differentiation of hPSCs. 
The most commonly used method to induce cardiomyocyte differentiation in vitro is the 
formation of three-dimensional aggregates, termed as embryoid bodies (EBs), 
consisting of cells representing the three germ layers59 EBs are usually formed in 
suspension cultures in the presence of bovine or human serum, followed by either 
plating on a gelatine-coated surface or further differentiated in suspension culture. 
Serum is used to provide the necessary differentiation signals, however its lot-to-lot 
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variations result in stochastic output of the differentiation, usually with a low yield of 
cardiomyocytes. Therefore growth factors and morphogenes are often used to direct the 
differentiation of hPSCs31, 60, 61, in the attempt to mimic the steps of in vivo 
cardiogenesis, namely mesoderm induction through Wnts, BMPs, or Nodal62-64, 
patterning of the mesoderm towards cardiogenic mesoderm, formation of cardiogenic 
mesoderm presumably through Wnt inhibition61 and Notch activity65, and finally 
maturation to early cardiomyocytes. In addition, small molecules such as 5-
azacytidine60, 66-68, cyclosporin-A69, or ascorbic acid67 are also often used to enhance 
cardiomyocyte differentiation from hPSC. 
In another widely used approach, undifferentiated hPSCs are co-cultured with 
mouse visceral endoderm-like (END-2) cells70, 71. While direct contact was reported to 
be important between END-2 cells and mouse ESCs or iPSCs for inducing 
cardiomyogenesis72, cardiac differentiation of enzymatically passaged hESC lines could 
be enhanced in END-2 conditioned medium (END2-CM) as well73, presumably due to 
factors secreted by END-2 cells. Biochemical analysis revealed elevated levels of 
prostaglandin I2 in END2-CM and its cardio-inductive effect was confirmed when a 
fully synthetic medium supplemented with prostaglandin I2 resulted in a cardiogenic 
activity equivalent to END2-CM74.  
An alternative protocol applied for cardiac differentiation is the monolayer 
culture of hPSCs on Matrigel-coated tissue culture plates in a feeder-free system31. To 
induce cardiac differentiation, MEF-conditioned medium used to maintain the 
pluripotent state is replaced with serum free RPMI-B27 medium supplemented with 
growth factors, such as BMP4 and activin A (as a mimic of Nodal).  
Recently several scalable systems have been developed to adequately supply the 
large numbers of cardiac cells required for drug screening or therapeutic applications. 
These systems are usually based on the use of a stirred-suspension bioreactor, providing 
a stable physicochemical environment, well-controlled aggregate sizes and yielding an 
order of magnitude more CMs than conventional differentiation methods75, 76. 
Besides directed differentiation cultures, other methods also exist to guide the 
differentiation of hPSCs towards the cardiac lineage, e.g. transgenic modification 
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through the delivery of cardiac specific transcription factors77  or recombinant 
proteins78. Since these methods are not closely related to the topic of the dissertation, 
further details are not provided here. However, a detailed review can be found in the 
attached book chapter Szebényi et al., “Human Stem-Cell-Derived Cardiomyocytes in 
Drug Discovery and Toxicity Testing”. 
 Another strategy to achieve an increased yield of CMs is to induce proliferation 
of mature hPSC-CMs that undergo progressive cell-cycle withdrawal during 
maturation79. Different cardiomyocyte cell-cycle reentry inducing extracellular factors 
have been reported, e.g. the fibroblast growth factor-1 (FGF-1) together with p38 MAP 
kinase inhibition80, periostin81 and Neuregulin-1β (NRG-1β)82, a cardioactive growth 
factor released from endothelial cells of the ventricular endocardium83. After it was 
shown that Neuregulin-1, induces proliferation of mononucleated, but not binucleated 
CMs in vivo82 another study demonstrated that inhibition of the signalling pathway 
involving NRG-1β and its tyrosine kinase receptor, ErbB4 enhances the proportion of 
cells showing nodal phenotype among hESC-derived CMs (60% nodal versus 40% 
ventricular subtype), while addition of exogenous NRG-1β resulted in the enhanced 
generation of CMs with ventricular phenotype (10% nodal versus 90% ventricular 
subtype)84. Direct differentiation of atrial and ventricular myocytes from hESCs has 
also been achieved by regulating Noggin and retinoid signals85. 
 
2.3. Systems allowing the isolation of human pluripotent stem cell-derived cardiac cells 
 Applicability of hPSC-derived cardiomyocytes depends not only on the large 
number of cells needed to be produced, but also on the purity of the cell population 
obtained at the end of differentiation. Therefore, the development of methods, allowing 
distinction between cardiac and other cell types is at least as relevant as the directed 
differentiation protocols. Isolation of living cells needed for drug screening, 
transplantation studies or basic research can be based on the use of genetically 
engineered reporter systems or cell surface markers.  Genetically modified features are 
specially required when markers of the cell type of interest are not located on the cell 
surface (e.g. transcription factors or sarcomeric proteins) and therefore selection would 
not be possible without disruption of the cell membrane. This was the case for 
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cardiomyocytes for a long time, previously to the identification of several surface 
markers co-expressing with cardiac-specific transcription factors and sarcomeric 
proteins72, 86, 87. Moreover, a cardiac-specific reporter hESC line could be successfully 
used for identification of surface markers of the cardiac lineage86, 88.  
  Increased yield of CMs as well as purification could also be achieved by 
isolation of progenitors (e.g. mesodermal, cardiac mesodermal, cardiovascular or 
cardiac progenitors, see Figure 3). Progenitors possess high proliferation capacity and 
restricted differentiation potential, allowing first the expansion of these cells by 
providing stage-specific renewal signals and then CM differentiation by cardio-
inductive signals. A culture condition supporting continuous self-renewal and 
proliferation of cardiovascular progenitors by inhibition of BMP, Activin/Nodal and 
glycogen synthase kinase 3 (GSK3) pathways have already been described89.  
 
 
Figure 3. Proposed progenitor stages of the differentiation of human pluripotent 
stem cells into cardiomyocytes. The progenitor stages are identified by transcription 
factors and structural proteins (shown in green bubbles) and cell surface markers 
(shown in grey bubbles). The image is taken from Szebényi et al. 148, with some 
modifications.  
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1.3.1 Genetic methods for isolation of hPSC-derived cardiac cells 
 Genetic modification of stem cells is less efficient than that of tumour-derived or 
immortalized cell lines, therefore generation of reporter-expressing cardiomyocytes 
raises some technical challenges (for further review see the attached book chapter 
Szebényi et al., “Human Stem-Cell-Derived Cardiomyocytes in Drug Discovery and 
Toxicity Testing”). However, by now several techniques have been documented to 
allow the generation of transgenic hPSC lines, without impairing self-renewal capacity 
and differentiation potential6, 90-92. Moreover, in most cases the studies demonstrated 
that the obtained cardiomyocytes were physiologically normal, regardless of the 
integration of the transgenes or the selection procedures applied for CM enrichment. 
Constitutive promoters, such as ACTB, UbC, EF1α, PGK, CMV or the original 
variant of the CAG provide nearly uniform transgene expression in all tissues; therefore, 
theoretically, these types of promoters cannot be used for isolation of CMs. However, it 
was demonstrated in differentiated hESCs that the activity of several commonly used 
constitutive promoters can be restricted to specific cell lineages, since ACTB was only 
active in undifferentiated and neuronal cells, while UbC and PGK were inactive in 
endothelial cells 93. Moreover, the CMV promoter became active only after mESCs 
differentiated into neuronal precursor cells 94, while the CAG promoter showed long-
term activity during mESC differentiation towards mesoderm 95. Still, reporter systems 
driven by various constitutive promoters (ACTB or CAG) could be reliable used for 
identification of transplanted transgenic hESC-derived CMs in infarcted mouse96 and 
rat97, 98 or healthy guinea pig heart99 to provide evidence for successful and functional 
engraftment.  
 Cardiac tissue specific promoters allow the isolation of cardiomyocytes, while 
progenitors able to give rise to cardiac cells can be obtained when the promoter of an 
early mesoderm or cardiac lineage-specific gene is used. The first well-defined cells 
able to give rise to the cardiac (besides of hematopoietic, vascular, and skeletal muscle) 
lineage are mesodermal progenitors, expressing the T-box factor BRACHYURY and 
the homeodomain protein MIXL1 (see Figure 3 for markers characteristic for specific 
stages of the cardiac differentiation). To allow selective isolation of mesodermal 
progenitors GFP expression cassette under the control of the BRACHYURY promoter 
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was randomly inserted into the genome100 or were targeted into the MIXL1 locus by 
homologous recombination101. More recently, a dual reporter system has been 
established where mesoderm posterior 1 (MESP1), a transcription factor characteristic 
for the pre-cardiac mesoderm is labelled with mCherry, while NKX2.5 (expressed later 
than MESP1) is labelled with EGFP, allowing isolation of progenitors at different stages 
of cardiac commitment102. For this dual reporter system a previously established hESC 
reporter line provided the basis, in which the GFP cDNA was introduced into the 
NKX2.5 locus by homologous recombination (NKX2.5eGFP/w)88. This NKX2.5eGFP/w 
reporter cell line allows the selection of multipotent cardiovascular progenitors, 
displaying cardiac, endothelial and vascular smooth muscle potential, similarly to the 
Cre/loxP system-based labelling of ISL1 expressing cells with the DsRed fluorescent 
reporter protein103. This system allows not only the selection of ISL+ cells, but also the 
lineage tracing of these cells, since the labelling is irreversible and DsRed expression 
does not attenuate with the downregulation of ISL1 expression.   
An alpha myosin heavy chain (αMHC) promoter-based system was used to 
follow maturation of hESC-derived cardiomyocytes over a year long36, and also to 
identify hESC-derived early myocardial precursors (αMHC-GFPpos) able to give rise to 
atrial ventricular and specialized conduction CM subtypes, but not to non-muscle 
cardiac cells104. Besides fluorescent proteins, drug resistance genes can also be used for 
enrichment of targeted cell populations. For example, hESC derived cardiomyocytes 
could be enriched to high purity (80-90%) when the puromycin resistance gene was 
driven by the αMHC promoter105, 106.  
Myosin light chain-2v (MLC-2V) is expressed later in CM differentiation than 
αMHC, therefore it does not allow the same insight into early CM differentiation, 
however, when the enhanced GFP was expressed under the control of the MLC-2V 
promoter, GFP expression-based identification and isolation of electrically active 
hESC-derived CMs was possible, according to Huber et al.107. It was also suggested 
that a short fragment of the cardiac troponin I (TNNI3) promoter in combination with 
the human cardiac alpha-actin enhancer is sufficient to identify hESC-derived CMs108.  
The disadvantage of these systems is that the activity of the transgene can only 
be detected at a certain stage of differentiation. To overcome this issue, Fu et al. applied 
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the combination of a constitutive and a tissue-specific promoter109.  In this system GFP 
expression was driven by the constitutive EF1α promoter to allow selection of 
successfully transduced undifferentiated hESCs, while MLC2V promoter-driven dsRed 
expression was applied to enrich for CMs with ventricular phenotype109109109109109106105.  
Stage-specific reporter systems offer several advantages, for example these 
systems can be used as readouts of culture optimization in a stage-specific manner or 
can be utilized in the search for new cell-surface markers of the different stages of the 
cardiac lineage. 
 
1.3.2 Non-genetic methods for isolation of cardiac cells 
 Mesodermal progenitors derived from hPSCs via epithelial-to-mesenchymal 
transition (EMT) can be selected not only by genetic methods, but also based on a cell 
surface marker combination, in which the neuronal cell adhesion molecule (NCAM or 
CD56) is used as positive, while the epithelial cell adhesion molecule (EpCAM or 
CD326) is used as negative marker110. However, the CD56posCD326neg marker 
combination was also documented to identify hESC-derived neuronal cells111, 
suggesting that markers or marker combinations may identify a progenitor population 
only in a culture dependent manner and when the differentiation is directed into another 
lineage or not directed at all, than specificity of the markers may diminish. In addition, 
upregulation of the tyrosine kinase transmembrane receptor (ROR2) can also be used to 
identify and select mesodermal progenitors112. 
Similarly to the above mentioned marker combination, the stage-specific 
embryonic antigen-1 (SSEA-1) has also been proposed to be a suitable marker, in this 
case for isolation of multipotent cardiovascular progenitors113, while others suggested 
SSEA-1 to be expressed on hESC-derived epithelial1 or neuroectodermal committed 
cell types114. Thus SSEA-1 may only allow identification of multipotent cardiovascular 
progenitors when the differentiation has already been efficiently directed into the 
cardiac lineage. 
 It was shown that low level expression of the vascular endothelial growth 
factor receptor 2 (VEGFR-2/KDR) together with the absence of the mast/stem cell 
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growth factor receptor, also known as proto-oncogene c-Kit or tyrosine kinase Kit (C-
KIT or CD117) identifies a population of cardiovascular progenitor cells (KDRlowC-
KITneg), expressing ISL1 and low levels of NKX2-5 and TBX561. This finding was 
verified not only on hESCs, but also in the case of hiPSCs115 and showed that mouse 
models are not always adequate for establishing human protein expression profiles, 
since in mice cardiac progenitors are c-KitposNkx2-5pos116, while during human cardiac 
differentiation the emergence of a C-KITposNKX2-5pos population could not be observed 
at all117.   
 In addition, it was also suggested that cardiovascular progenitors can be 
identified based on the co-expression of KDR and PDGFRA64. However, the same 
research group demonstrated later that not all of the KDRposPDGFRApos cells give rise 
to cells of the cardiac lineage86. In addition, isolation based on KDR expression may 
result in an impure population of cardiovascular progenitors, since KDR is also 
expressed on hPSCs61. 
 The NKX2-5eGFP/w reporter system was used to screen for new cell-surface 
markers of the cardiac lineage, resulting in the discovery of two early CM markers, 
namely vascular cell adhesion molecule 1 (VCAM1) and signal regulatory protein α 
(SIRPA)88. Further experiments showed that VCAM1 positivity appears slightly later 
than SIRPA, and NKX2-5posSIRPAposVCAM1pos cardiomyocytes arose from an NKX2-
5posSIRPApos intermediate117.  
 Upregulation of SIRPA happened parallel to the emergence of the first NKX2-
5–GFPpos cells (around day 8 of the differentiation), a day before the spontaneous 
contractile activity started in the differentiation cultures of HES2 hESCs86. Thus 
SIRPApos cells isolated at EB day 8 were considered as cardiac precursors and were 
shown to be able to give rise to troponin expressing SIRPApos CMs. Therefore it was 
concluded that SIRPA is a cell surface marker able to identify cardiac precursors and 
cardiomyocytes.  
 VCAM1 was shown to allow isolation of CMs but not cardiac progenitors, 
since troponin expression preceded VCAM1 appearance during differentiation118. 
VCAM1 expression based selection on day 11 of the differentiation resulted in a 
population of highly purified (>95%) CMs in the case of all four hPSC lines examined, 
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although VCAM1pos cells represented only a subset within troponin T-positive cells 
(33.4%-63.5%).   
 The activated leukocyte cell adhesion molecule (ALCAM or CD166) is another 
marker, that have been suggested to enable isolation of hESC-derived CMs87, and later 
it was also shown that ALCAM allows the high-purity enrichment of hiPSC-derived 
CMs as well115. In this latter work first KDRlowC-KITneg multipotent cardiovascular 
progenitors were isolated on EB day 6 and recultured as monolayer, than on day 20 of 
the differentiation CD166 was used to select CD166pos CMs and CD166neg smooth 
muscle cells. However, it is important to mention that there is only a short, early 
developmental stage-specific time window when ALCAM expression is restricted to 
cardiomyocytes, and beyond this particular developmental stage ALCAM expression is 
widespread among different types of tissues115, 119-121. 
The first non-genetic method reported in the literature allowing the isolation of 
living cardiomyocytes was based on the high mitochondrial content of CMs, resulting in 
that tetramethylrhodamine methyl ester perchlorate (TMRM), a fluorescent dye 
specifically labelling mitochondria could be used for cardiomyocyte enrichment with a 
purity of 99%122. However, it was shown that this method allows only the selection of 
late-stage CMs, while early CMs could not be discriminated from undifferentiated 
hESCs88.  
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3. Aims 
 
The goal of the research presented in the dissertation was to establish a novel in 
vitro method for the purification of human embryonic stem cell-derived cardiomyocytes 
and cardiac progenitors. In order to achieve this objective, the aims of the present study 
were: 
 
1. To demonstrate that the CAG promoter provides the opportunity to identify 
cardiomyocytes in spontaneous differentiation cultures of human embryonic stem cells.  
2. To induce cardiac differentiation of human embryonic stem cells in order to enrich 
the differentiation cultures for cardiac progenitors. 
3. To demonstrate that the CAG promoter provides the possibility to identify and isolate 
cardiac progenitors during directed differentiation of human embryonic stem cells. 
4. To find optimal culture conditions for isolated cardiac progenitors to maintain cardiac 
commitment during further differentiation.  
5. To demonstrate that the isolated human embryonic stem cell-derived cardiac 
progenitors can be differentiated into relatively pure population of cardiomyocytes.   
6. To optimize reaggregation and survival properties of isolated human embryonic stem 
cell-derived cardiac progenitors to enhance cardiomyocyte yield.  
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4. Materials and Methods 
4.1. hESC culture and differentiation 
The original HUES9 human embryonic cell line was kindly provided by Dr. 
Douglas Melton from the Harvard University, while BG01V was purchased from 
ATCC. The Sleeping Beauty (SB) transposon based gene delivery method was applied 
to genetically modify HUES9 and BG01V hESCs with a plasmid containing the cDNA 
of the fluorescent protein EGFP, under the control of a specific variant of the CAG 
promoter (SB-CAG-EGFP construct) 90. This specific variant contains a CMV enhancer 
region, two sequences from the chicken β-actin promoter and one short part of the rabbit 
β1-globin promoter 90.  
HUES9-CAG-EGFP and BG01V-CAG-EGFP hESC colonies were cultured on 
mitomycin-C treated mouse embryonic fibroblast (MEF) feeder cells (MERCK 
Millipore), in a medium consisting of Knockout DMEM (Life Technologies), 
supplemented with 20% Knockout Serum Replacement (Life Technologies), 2 mM 
glutamine, 0.1 mM nonessential amino acids, 0.1 mM β-Mercaptoethanol and 15 ng/ml 
recombinant human basic fibroblast growth factor (bFGF).  
 
 
Figure 4. Schematic outline of spontaneous differentiation through the EB 
formation method. 
 
Figure 4 shows the schematic outline of the spontaneous differentiation protocol, 
designated as the embryoid body (EB) formation method. Differentiation was initiated 
via EB formation under suspension culture conditions, ensured by an ultra-low 
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attachment surface of the culture plate and an EB medium containing Knockout 
DMEM, 20% ES-tested FBS (Life Technologies), 1% NEAA, 0,2% β-merkaptoethanol 
and 1% L-glutamin. On the 6th day of differentiation EBs were plated onto gelatine 
coated 24 well plates, in a density of 5-10 EBs/well. From this time point EBs were kept 
in differentiation medium (DM) containing DMEM (Life Technologies) and 10% EU-
tested FBS (Life Technologies).  
Directed differentiation of HUES9-CAG-EGFP and BG01V-CAG-EGFP cells was 
initiated via EB formation in suspension, as previously reported 61, with some 
modifications, as shown in the Results. Spontaneously contracting cardiomyocytes 
appeared at day 14-16 of the differentiation in both cases. 
 
4.2. Flow cytometry  
Undifferentiated HUES9-CAG-EGFP colonies were harvested from mouse feeder 
cells by enzymatic digestion with 0.05% trypsin-EDTA (Gibco), HUES9-CAG-EGFP 
EBs were dissociated with 0.25% trypsin-EDTA (Gibco). Single cell suspension was 
washed with PBS containing 0.5% bovine serum albumin and incubated for 30 min at 
37 °C with the following directly labelled monoclonal antibodies: anti-human SSEA4-
PE antibody (R&D System Inc., Minneapolis, MN) for specific labeling of pluripotent 
cells, anti-human CD166-A647 antibody (AbD Serotec) for specific labeling of 
activated cell adhesion molecule (ALCAM) expressing cells, CD106-PE for specific 
labeling of Vascular Cell Adhesion Molecule-1 (VCAM1) (BD Pharmingen) and anti-
mouse Sca-1 (Ly-6A/E)-PECy5.5 (Beckton-Dickinson, San Jose, CA) antibody for 
specific labelling of mouse feeder cells in the case of undifferentiated cells (sample D0) 
and 6 day-old EBs (sample D6). The unconjugated monoclonal antibody SIRPA 
(BioLegend) was labelled with Alexa Fluor 647-conjugated goat anti-mouse IgG 
antibody (Invitrogen). For intracellular staining the cells were fixed and permeabilized 
with 4% paraformaldehyde (PFA) in PBS, subsequently the staining with anti-Troponin 
I (Monoclonal Anti-TNNI3, 1:500 dilution, Sigma) labelled with Alexa Fluor 647-
conjugated goat anti-mouse IgG antibody (Invitrogen) was performed in PBS with 2% 
BSA and 0.75% Saponin (Sigma). Control staining with appropriate isotype-matched 
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control antibodies or background levels of fluorescence of the fluorochrome-conjugated 
secondary antibody was included. Dead cells were gated out based on 7AAD (Sigma) 
staining. HUES9 cells were measured to set the level for EGFP-positivity of 
undifferentiated HUES9-CAG-EGFP cells.  Samples were analyzed by a FACSCalibur 
flow cytometer (Beckton-Dickinson, San Jose, CA) equipped with a 488 nm argon laser 
and a 635 nm red diode laser with BD CellQuest acquisition software (BDIS) or by 
FACSAria High Speed Cell Sorter (Beckton-Dickinson, San Jose, CA) with BD 
FACSDiva software.  
 
4.3. Cell sorting  
HUES9-CAG-EGFP EBs were dissected with 0.25% Trypsin-EDTA and single cell 
suspension was sorted into artificial fractions (low, mid and high) based on EGFP 
fluorescent signal intensity using the fluorescence based FACSAria High Speed Cell 
Sorter (Beckton-Dickinson, San Jose, CA). Minimum linear value within the CAG-
EGFPlow fraction was 3000, maximum linear value was 15500; for the CAG-EGFPhigh 
fraction minimum linear value was 29500, while maximum linear value was 262000. 
Precision of the sorting procedure was monitored by EGFP expression profiling of 
the sorted fractions with flow cytometry, immediately after sorting (see Results). Cells 
obtained from the different fractions were washed with sterile PBS and either recultured 
or immediately resuspended in Trizol (Invitrogen, Carlsbad, CA, 
http://www.invitrogen.com) for further gene expression analysis. Isolated cells were 
placed into NUNC HydroCell Surface 96 well plates in a density of 30,000 cells/well, 
unless stated otherwise. 
 
4.4. Fluorescence plate reader measurements 
For fluorescence plate reader measurements a VICTOR X3 2030 Multilabel Reader 
(Perkin Elmer) was used. EBs reaggregated from the sorted cells (rEBs) were cultured 
in NUNC HydroCell Surface 96 well plates and fluorescence measured 3 and 20 days 
after sorting (see Results). Excitation wavelength was 490 nm, and a F535 emission 
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filter was used for detection of EGFP fluorescence. Fluorescence intensity levels were 
calculated as averages of 9 independent measurements.  
Propidium iodide (PI) staining was carried out 3 and 20 days after sorting, in order 
to assess the growth of the rEBs and estimate changes in cell numbers. The rEBs were 
fixed with methanol on ice for 15 minutes and, after a washing step, were stained with 
PI. After incubation with PI for 15 minutes the rEBs were transferred into fresh PBS in 
a 96 well plate (Greiner). Excitation wavelength was 540 nm, and a F660 emission filter 
was used for detection of PI fluorescence. Fluorescence intensity levels were calculated 
as averages of 6 independent experiments.  
 
4.5. Immuncytochemistry 
For immunostaining, whole EBs were differentiated either on gelatin-coated 8 
chamber dishes with glass bottom (Imaging chambers, PAA) or on 24 well culture 
plates, while EBs reaggregated from the sorted cells (rEBs), were plated onto gelatin-
coated 8 chamber dishes with glass bottom, 6-7 days after the sorting procedure. To 
achieve adequate adherence of the rEBs, a 5 minute trypsinization procedure was 
performed with a 0.25% Trypsin-EDTA solution. EBs and rEBs were fixed with 4% 
paraformaldehyde in Dulbecco's modified Phosphate Buffered Saline (DPBS) for 15 
min at room temperature. After three washing steps with DPBS, nonspecific antibody 
binding was blocked for 1 h at room temperature in DPBS containing 2 mg/ml bovine 
serum albumin, 1% fish gelatin, 5% goat serum and 0.1% Triton-X 100. The samples 
were then incubated for 1 h at room temperature with the primary antibodies. The 
primary antibodies used were: anti-Troponin I (Monoclonal Anti-TNNI3, 1:500 
dilution, Sigma), Pecam (Anti-Human PECAM-1, 1:500 dilution, eBioscience), SMA 
(Monoclonal Anti-Actin, Alpha-Smooth Muscle, 1:100 dilution, Sigma), AFP 
(Monoclonal Anti-alpha-Fetoprotein, 1:500 dilution, Sigma), βIII-Tubulin (Monoclonal 
Anti-Neuron-specific beta-III Tubulin, 1:2000 dilution, R&D Systems). After washing 
with DPBS, the cells were incubated for 1 hour with the secondary antibodies at room 
temperature. Secondary antibodies were diluted in the blocking solution at 1:250 in each 
case. Alexa Fluor 568-conjugated goat anti-mouse IgG antibody (Invitrogen) was 
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applied to detect troponin I, AFP, βIII-Tubulin. DAPI (Invitrogen, Madison, WI) was 
used for nuclear staining (10 µM, 10 minute-long incubation in DPBS). Samples stained 
on 8 chamber dishes with glass bottom were examined by an Olympus FV500-IX 
confocal laser scanning microscope, while samples stained on 24 well plastic culture 
plates were examined by fluorescence microscopy. At least two independent samples 
were used in each measurement. 
 
4.6. Real-time quantitative PCR analysis 
Total RNA was isolated from cells using TRIzol™ Reagent (Invitrogen) following 
the manufacturer’s instructions. cDNA samples were prepared from 0.2 µg total RNA 
using the Promega Reverse Transcription System Kit as specified by the manufacturer. 
For real-time quantitative PCR (QPCR)  the following Pre-Developed TaqMan® assays 
were purchased from Applied Biosystems: NANOG as undifferentiated stem cell 
marker; BRACHYURY as early mesodermal marker; ISL1, TBX5, NKX2.5 and GATA4 as 
early markers of cardiac differentiation; TNNT2, PLN and NPPA as cardiac specific 
marker; ALCAM as stage specific cardiac marker; MYL2 as ventricular-, MYL7 as atrial-, 
HCN4 as nodal subtype specific marker; P0 ribosomal protein as endogenous control for 
quantification. QPCR analyses were carried out using the StepOne™  Real-Time PCR 
System (Applied Biosystems), according to the manufacturer’s instructions. The fold-
change of mRNA in experimental and control cells was determined using the 2-∆∆Ct 
method. Relative mRNA levels were presented as mean values ± S.E.M. of 3 
independent experiments. Levels of significance were calculated by the two-tailed 
Student t-test. 
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5. Results 
5.1. The CAG promoter allows the identification of cardiomyocytes in spontaneous 
differentiation cultures of human embryonic stem cells 
5.1.1. Characterization of the hESC lines HUES9-CAG-EGFP and BG01V-CAG-EGFP  
EGFP expressing HUES9 and BG01V cells were generated by transfection with 
the SB-CAG-EGFP construct (see Materials and Methods). The genetic modification 
was carried out by the research group of Tamás Orbán. Transgenic hESC lines 
(HUES9-CAG-EGFP and BG01V-CAG-EGFP) were established through the 
enrichment of EGFP expressing hESCs by sorting or cloning. Several cell lines have 
been established with different EGFP expression intensities, either completely free of 
transgene-negative (CAG-EGFPneg) cells or containing a small population of CAG-
EGFPneg cells.    
 
 
Figure 5. Characterization of HUES9-CAG-EGFP cells. (A) Fluorescence 
microscopy image of HUES9-CAG-EGFP colonies on MEF feeder layer, showing 
hESC-like morphology. (B) Confocal microscopy images of HUES9-CAG-EGFP 
colony on MEF feeder layer, showing expression of the pluripotency marker OCT4. (C) 
Flow cytometry measurement of SSEA4-APC and its isotype control IgG3-APC in 
HUES9-CAG-EGFP cells.   
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HUES9-CAG-EGFP cells were cultured on a mouse embryonic fibroblast (MEF) 
feeder layer and maintained pluripotency during long-term culture, as demonstrated by 
the colony (clump) morphology characteristic for pluripotent hESCs (Figure 5A), by 
immunostaining against the pluripotency marker OCT4 (Figure 5B) and by flow 
cytometry measurement detecting SSEA4 expression (Figure 5C).  
Similarly to the HUES9-CAG-EGFP hESC line, BG01V-CAG-EGFP clumps 
were also cultured on MEF feeder layer (Figure 6A) and expressed OCT4 (Figure 6B) 
and SSEA4 (Figure 6C), respectively. Flow cytometry measurements detecting SSEA4 
expression were routinely carried out to monitor the pluripotent state of hESCs during 
long term culture. Only hESCs with more than 95% SSEA4 positivity were used for 
experiments.  
 
 
Figure 6. Characterization of BG01V-CAG-EGFP cells. (A) Fluorescence 
microscopy image of BG01V-CAG-EGFP colonies on MEF feeder layer, showing 
hESC-like morphology. (B) Confocal microscopy images of BG01V-CAG-EGFP 
colony on MEF feeder layer, showing expression of the pluripotency marker OCT4. (C) 
Flow cytometry measurement of SSEA4-APC and its isotype control IgG3-APC on 
BG01V-CAG-EGFP cells.   
 
Pluripotency of hESC lines is also characterized by the ability of differentiating 
into the three germ layers, namely into the endoderm, ectoderm and mesoderm lineages. 
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HUES9-CAG-EGFP cells were differentiated through the EB method, which is often 
used for initiating spontaneous differentiation. Loss of pluripotency and mesodermal 
commitment was investigated by QPCR, detecting the downregulation of the 
pluripotency marker NANOG and the upregulation of the early mesodermal marker gene 
BRACHYURY during the first 12 days of differentiation (Figure 7A). Downregulation 
of BRACHYURY was followed by the upregulation of the early cardiac marker genes 
GATA4, NKX2.5 and ALCAM, indicating the emergence of cardiac-committed cells in 
the differentiation culture around the10th day of the differentiation (Figure 7B).  
 
 
Figure 7. Transcriptional profile of spontaneous differentiation of HUES9-
CAG-EGFP cells. (A) QPCR analysis of the mRNA expression of NANOG and 
BRACHYURY in whole EBs at early stages of differentiation. (B) QPCR analysis of the 
mRNA expression of ALCAM, GATA4 and NKX2.5 in whole EBs at different stages of 
spontaneous differentiation.  
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Figure 8. Immunocytochemistry analysis of spontaneously diffferentiating HUES-
CAG-EGFP cells. Green: CAG-EGFP. Blue: DAPI. (A) Anti-alpha-fetoprotein (AFP) 
and anti-neuron-specific beta-III-tubulin (βIII-Tub) staining of HUES9-CAG-EGFP 
EBs on day 12 of the differentiation. (B) Anti-platelet endothelial cell adhesion 
molecule (PECAM-1) and anti-alpha-smooth muscle actin (SMA) staining of HUES9-
CAG-EGFP EBs on day 22 of the differentiation. The image is taken from Szebényi et 
al.123, with some modifications. 
 
The emergence of cells of the other two germ layers was demonstrated by 
immunocytochemistry studies (Figure 8A). On day 12 of the differentiation (D12) EBs 
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were stained against the early endoderm marker alpha-fetoprotein (AFP) and the 
ectoderm marker beta-III-tubulin (βIII-Tub), and both endodermal and ectodermal cells 
were found to be present in the differentiation culture. Cells of the mesodermal lineages 
were identified based on the expression of alpha-smooth muscle actin (SMA), 
characteristic for smooth muscle cells and based on platelet endothelial cell adhesion 
molecule (PECAM-1) expression, characteristic for endothelial cells, respectively 
(Figure 8B). The expression of SMA and PECAM was investigated on day 22 (D22) of 
the differentiation, since cells positive for these markers emerge only at later stage of 
the differentiation. Besides smooth muscle and endothelial cells, cardiomyocytes are 
also of mesodermal origin. Cardiac differentiation was demonstrated by the emergence 
of numerous spontaneously contracting areas during later stage of differentiation (after 
14 days).   
 
5.1.2. In differentiation cultures of HUES9-CAG-EGFP and BG01V-CAG-EGFP 
cardiomyocytes show exceptionally high EGFP expression 
Spontaneous differentiation of HUES9-CAG-EGFP hESCs usually resulted in 
numerous spontaneously contracting areas with extremely high EGFP fluorescence 
signal intensity, masking dimmer fluorescence of the surrounding tissues (Figure 9, 
white arrows pointing on the contracting areas with high EGFP signal). Extremely high 
EGFP expression intensities were predominantly observed onsite of the contracting 
areas (Supplementary video 1) and allowed the identification of cardiomyocytes in the 
differentiation culture based alone on their extremely high EGFP expression intensities. 
Two different hESC lines (HUES9-CAG-EGFP and BG01V-CAG-EGFP) and a mouse 
ESC line (R1-CAG-EGFP, kindly provided and differentiated by Elen Gócza) were 
used to demonstrate that this effect is cell line and species-independent (Figure 9). 
Moreover, it was shown by Tamás Orbán and co-workers that this phenomenon is 
exclusively dependent on the CAG promoter and independent of the transgene 
integration site and copy number, the transgene sequence, as well as the method of gene 
delivery. A detailed description of the experiments resulting in this conclusion can be 
found in the attached paper, Orbán et al.90.  
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Figure 9. Fluorescence microscopy images of spontaneously contracting areas. The 
images show spontaneously contracting areas differentiated from two different human 
embryonic stem cell lines (HUES9-CAG-EGFP and BG01V-CAG-EGFP) and from a 
mouse embryonic stem cell line (R1-CAG-EGFP) at two different magnifications.  
 
To elicit whether the extremely high EGFP expression intensities of 
cardiomyocytes are the result of higher transcription or translation rate, or certain 
posttranslational modifications, HUES9-CAG-EGFP differentiation cultures were 
separated into three fractions based on EGFP fluorescence by a FACSAria High Speed 
Cell Sorter at the 30th day of differentiation (Figure 10A). The data presented in 
Figure 10 are the result of a differentiation, repeated independently from the 
experiments published by Orbán et al. In this particular experiment the applied HUES9-
CAG-EGFP hESC line contained a subpopulation of EGFP negative cells (Figure 10A, 
yellow population), superseding the use of the HUES9 cell line as negative control for 
setting up the detection of the EGFP signal. EGFP negative cells were not included in 
further analysis since this population contained a mixture of all types of cells emerging 
during differentiation. The fraction containing cells with exceptionally high EGFP 
fluorescent signal intensity was designated as the CAG-EGFPhigh subpopulation (Figure 
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10A, green), while cells with low EGFP intensity as the CAG-EGFPlow subpopulation 
(Figure 10A, blue). Cells between these two fractions were designated as CAG-
EGFPmid (Figure 10A, purple).  
Sorted cells were resuspended in TRIzol Reagent to isolate total cellular RNA 
from each of the separated fractions. Real-time quantitative PCR analysis revealed that 
EGFP transcription levels closely correlated with the fluorescent signal intensities of the 
fractions, thereby providing evidence for increased transcription through increased 
promoter activity as the cause of enhanced EGFP fluorescent signal intensity (Figure 
10B). Therefore higher nucleus-cytoplasm ratio in cardiomyocytes compared to other 
cell types could also be excluded as the cause of this phenomenon. 
 
 
Figure 10. The CAG-EGFPhigh subpopulation is enriched in cardiomyocytes.  
(A) Isolation of CAG-EGFPlow (blue), CAG-EGFPmid (purple) and  CAG-EGFPhigh 
(green) fractions from HUES9-CAG-EGFP EBs based on the CAG-EGFP signal 
intensity on day 32 of the differentiation. (B) QPCR analysis of the mRNA expression 
of GFP, ALCAM, NKX2.5, GATA4, PLN and NPPA in EBs at day 32 of spontaneous 
differentiation. (C) QPCR analysis of the mRNA expression of PAX6 and CAPG in EBs 
at day 32 of spontaneous differentiation. 
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Transcriptional profiles of cardiac-specific (NKX2.5, GATA4, ALCAM, PLN and 
NPPA), early neuron-specific (PAX6), and skin-specific (CAPG) marker genes 
measured by QPCR revealed that the CAG-EGFPhigh fraction contained higher level of 
cardiac-specific mRNA than the other two fractions, while neuron and skin-specific 
mRNA was underrepresented in this sample compared to the other two fractions 
(Figure 10B). These findings proved that apart from being constitutively functional in 
all cell types (including undifferentiated hESCs, see Figure 5 and 6) this specific 
variant of the CAG promoter was transcriptional extremely active in cardiac tissues, 
providing the possibility for selection of transgene expressing hESCs and hESC-derived 
CMs, and therefore it was named as “double-feature” promoter90.  
 
 
Figure 11. Non-contracting areas expressing CAG-EGFP at a very high intensity 
are cardiomyocytes, but not all of the cardiomyocytes express CAG-EGFP at an 
exceptionally high level. (A) Fluorescence microscopy images at two different 
magnifications of a non-contracting area expressing CAG-EGFP at an exceptionally 
high level. (B) Fluorescence microscopy images at two different magnifications of 
cardiac troponin I (cTnI) staining of the same area. Blue: DAPI. Green: CAG-EGFP. 
Red: cTnI. The white arrow indicates a cTnI positive area with lower EGFP signal 
intensity. The image is taken from Szebényi et al.123, with some modifications. 
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Besides of numerous contracting areas several non-contracting areas with 
exceptionally high EGFP signal intensities were spotted by fluorescent microscopy 
during examination of the differentiation cultures, even at later stages of the 
differentiation (Figure 11A). To further support the previous finding, namely that the 
transcriptional activity of the CAG promoter is higher selectively in cardiomyocytes, 
wells of 24-well plates containing such non-contracting areas were stained against 
cardiac troponin I (cTnI). Figure 11B shows a representative cTnI staining, 
demonstrating good colocalization with the enhanced EGFP signal, as well as the 
existence of cardiomyocytes (cTnI positive cells) with lower EGFP signal intensity 
(Figure 11B, white arrow). 
 
 
Figure 12. Fluorescence microscopy images of the same area showing exceptionally 
high EGFP expression during the course of spontaneous differentiation of HUES9-
CAG-EGFP culture. Onset of the spontaneous contractile activity is denoted by a 
white heart symbol. White arrows indicate the areas with extremely high EGFP signal.  
 
Next, the appearance of areas with exceptionally high EGFP signal was 
investigated by fluorescent microscopy at early stages of spontaneous differentiation 
and selected areas were followed during the course of differentiation to evaluate the 
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ability of the CAG promoter to identify progenitors of cardiomyocytes (Figure 12). 
This was important because the selection of mature cardiomyocytes is limited by their 
poor reaggregation and survival properties as single cells, while cardiac progenitors 
possess better reaggregation and survival properties. In addition, cardiomyocytes 
undergo progressive cell-cycle withdrawal during maturation79, while progenitor cells 
are still able to divide, therefore cardiomyocyte yield of the differentiation can also be 
enhanced by selective propagation of cardiac progenitors.  
Day 10 was found as the earliest time point when cells further differentiating to 
contracting cardiomyocytes could be identified based on their high EGFP expression 
(Figure 12). These findings suggested that the CAG promoter would allow not only the 
isolation of cardiomyocytes, but also that of cardiac progenitors, since the contractile 
activity, indicating the appearance of cardiomyocytes started only later, after day 14 in 
the differentiation cultures.  
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5.2. Directed cardiac mesoderm differentiation of CAG-EGFP expressing human 
embryonic stem cells   
To facilitate the examination of the ability of the CAG promoter to identify 
cardiac progenitors, spontaneous differentiation was needed to be replaced by a 
differentiation protocol which is able to enrich the output of the differentiation for cells 
with mesoderm origin. The original protocol was obtained from the literature61 and was 
optimized for CAG-EGFP expressing hESCs, however, some basic modifications were 
introduced to render it affordable for routine use in a small academic laboratory.  
Figure 13 shows the outline of the protocol used to induce mesodermal 
differentiation. Bone morphogenetic factor-4 (BMP4), Activin A, ascorbic acid and 
monothioglycerol  (MTG)  was used to differentiate cells towards the mesoderm, while 
further commitment to the cardiac mesoderm was supported by the addition of ascorbic 
acid and MTG alone. Formation of cells of the cardiovascular lineages was achieved in 
differentiation medium (DM) supplemented with ascorbic acid and MTG, added until 
the 14th day of the differentiation. 
 
 
Figure 13. Schematic representation of the protocol for directed differentiation. 
The image is taken from Szebényi et al.123, with some modifications. 
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Directed differentiation was monitored by fluorescence activated cell sorting 
(FACS) measurements and its kinetics was compared to that of spontaneous 
differentiation (Figure 14). The loss of pluripotency demonstrated by the decrease of 
SSEA4 expression could be detected earlier, already on day 6 in the directed 
differentiation culture, while during spontaneous differentiation SSEA4 expression 
started to decline only around D10 (Figure 14A).  
ALCAM can be designated as a cardiomyocyte marker, but it is important to 
mention that ALCAM is expressed solely on cardiomyocytes at an early developmental 
stage-specific manner, while beyond this particular developmental stage ALCAM 
expression is widespread among different types of tissues115, 119-121. Therefore it was 
important to examine the kinetics of ALCAM expression during the course of 
differentiation of HUES9-CAG-EGFP cells. Directed differentiation resulted ALCAM 
positive cells around day 9, while during spontaneous differentiation ALCAM positive 
cells emerged later (around day 12).     
To further examine mesoderm differentiation the cell surface expression of KDR 
(VEGF-R) and CD117 (C-KIT) was monitored during the first 12 days of the 
differentiation (Figure 14B), based on the paper of Yang et al., showing that the 
KDRlow/CD117neg subpopulation indicate the presence of cardiovascular progenitors 
during directed differentiation of hESCs61.  In the directed differentiation cultures 
increased presence of this population could be observed between day 6 and day 12, 
while in spontaneous differentiation cultures the KDRlow/CD117neg subpopulation 
evolved only later, around day 9 and composed a smaller fraction of the culture as 
shown in Figure 14B. 
Counting of contracting areas served as a readout for cardiac differentiation 
efficiency. Directed differentiation resulted more contracting areas than spontaneous 
differentiation (Figure 14C). Figure 14D shows that this difference could be 
demonstrated by FACS measurement of undifferentiated (light grey) and differentiated 
HUES9-CAG-EGFP samples (dark grey for spontaneous or black for directed 
differentiation) stained against cTnI.  
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Figure 14. Comparison of spontaneous and directed differentiation. (A) Flow 
cytometry analysis of SSEA4 and ALCAM/CD166 on cells from whole HUES9-CAG-
EGFP EBs at different stages of spontaneous (upper row) and directed differentiation 
(lower row). (B) Flow cytometry analysis of C-KIT/CD117 and KDR on cells from 
whole HUES9-CAG-EGFP EBs at different stages of spontaneous (upper row) and 
directed differentiation (lower row). (C) Table summarizing the outcome of a 
spontaneous and a directed differentiation in terms of contracting areas (CAs)-content 
on a 24 well plate at day 30 (D30). (D) Flow cytometry analysis of cardiac troponin I 
(cTnI) staining of undifferentiated and differentiated (spontaneous or directed) samples. 
For flow cytometry analysis the FACSCalibur flow cytometer was used; dot plot gates 
were set based on the isotype controls.   
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Figure 15 shows the transcriptional profile of directed differentiation measured 
by QPCR. By day 2 of the directed differentiation a rapid downregulation of the mRNA 
expression of the pluripotency gene NANOG was observed, followed by a transient 
upregulation of BRACHYURY mRNA level, implying the formation of the mesoderm 
(Figure 15A). BRACHYURY was already downregulated by day 8, while during 
spontaneous differentiation downregulation of the same gene happened only later, 
around day 12 (see Figure 7). Cardiac specific genes such as ISL1, TBX5, NKX2.5, 
TNNT2 and ALCAM were used to confirm the emergence of cardiac mesoderm in the 
directed differentiation cultures (Figure 15B). ISL1 expression was upregulated on day 
6, preceding the upregulation of TBX5 and NKX2.5 expression on day 8. The expression 
of TNNT2 mRNA become detectable at a low level on day 6, but a high level expression 
was associated with the emergence of spontaneous contractile activity and occurred 
around day 14. Upregulation of ALCAM mRNA levels overlapped with the upregulation 
of ISL1, and was maintained thereafter.  
 
Figure 15. Transcriptional profile of directed differentiation of HUES9-CAG-
EGFP cells. (A) QPCR analysis of the mRNA expression of NANOG and 
BRACHYURY in EBs at early stages of differentiation. (B) QPCR analysis of the 
mRNA expression of ISL1, TBX5, NKX2.5, ALCAM and TNNT2 in EBs at different 
stages of directed differentiation. Levels of significance were calculated by the Student 
T-test; *: p<0.05, n=3. The image is taken from Szebényi et al.123. 
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As shown in Figure 16, a well measurable EGFP expression could be detected 
by FACS in the pluripotent state (D0) of HUES9-CAG-EGFP cells, together with a high 
level of SSEA4 expression. Further analysis of HUES9-CAG-EGFP differentiation by 
FACS revealed a slight decrease in the EGFP signal during the suspension culture stage 
of the differentiation. However, on day 10 the formation of a subpopulation expressing 
EGFP at a very high level could be confirmed (Figure 16, black arrows).  This CAG-
EGFPhigh subpopulation was negative for SSEA4 and its appearance on day 10 
anticipated the onset of the spontaneous contractile activity (D14 and later) by four days 
at least. Therefore it was hypothesized that the ideal period for isolation of cardiac 
progenitors based on the CAG-EGFP signal is between day 10 and day 14 of the 
differentiation. 
 
 
Figure 16. Flow cytometry analysis of the pluripotency marker SSEA4 and the 
CAG-EGFP on cells from whole HUES9-CAG-EGFP EBs at different stages of 
differentiation. Dot plot gate for SSEA4 expression was set based on the isotype 
control, IgG3-PE. Arrows indicate the evolving CAG-EGFPhigh/SSEA4neg 
subpopulation. The image is taken from Szebényi et al.123, with some modifications. 
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5.3. The CAG promoter allows identification and isolation of human embryonic stem 
cell-derived cardiac progenitors  
5.3.1. Isolation and mRNA expression profiling of the CAG-EGFPhigh subpopulation  
In order to assess whether the CAG-EGFP signal intensity allows the 
identification and isolation of cardiac progenitors, cell sorting was performed from the 
trypsinized cultures of differentiating HUES9-CAG-EGFP cells and transcriptional 
profile of the isolated samples were compared by QPCR.  
As shown in Figure 17 two separate cell populations, namely CAG-EGFPhigh 
(indicated by blue colour) and CAG-EGFPlow (indicated by red colour) were isolated by 
a FACSAria High Speed Cell Sorter on day 10 (D10) and 12 (D12) of the 
differentiation. The sorted fractions were re-measured by FACS to establish sorting 
purity. 
 
Figure 17. Isolation of CAG-EGFPlow (red) and CAG-EGFPhigh (blue) fractions 
from HUES9-CAG-EGFP EBs based on the CAG-EGFP signal intensity on day 10 
(D10) and day 12 (D12) of the differentiation. The sorted subpopulations were re-
analyzed by FACS measurements to establish sorting purity of CAG-EGFPhigh (lower 
row) and CAG-EGFPlow (middle row) cells. Green coloured cells were not analysed. 
The image is taken from Szebényi et al.123. 
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QPCR analysis revealed that the CAG-EGFPhigh samples expressed significantly 
higher levels of the cardiac specific genes ISL1, TBX5 and TNNT2 than the CAG-
EGFPlow samples, while NKX2.5 mRNA levels were higher in the CAG-EGFPlow 
fractions at both days of differentiation examined (D10 and D12) (Figure 18A). In 
CAG-EGFPhigh samples expression levels of the NKX2.5 transcripton slightly increased 
from day 10 to day 12, while in the case of CAG-EGFPlow cells a robust decrease was 
observed. Figure 18A also shows that expression levels of the ALCAM transcript were 
similar in the sorted fractions on day 10, but by day 12 the two fractions clearly 
separated from each other and CAG-EGFPhigh cells expressed ALCAM at a significantly 
higher level than CAG-EGFPlow cells (Figure 18A).  
Figure 18B shows that the early neuronal markers, SOX1 and PAX6, as well as 
the early endoderm marker AFP were expressed at higher levels in the CAG-EGFPlow 
samples. Expression of the pluripotency genes OCT4 and NANOG was also investigated 
and two magnitude of order less transcript were found in isolated samples than in 
undifferentiated HUES9-CAG-EGFP cells, used as positive control (Figure 18C). 
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Figure 18. The CAG-EGFPhigh subpopulation is enriched in cardiac progenitor 
cells. (A) QPCR analysis of the mRNA expression of ISL1, TBX5, NKX2.5, ALCAM 
and TNNT2 in HUES9-CAG-EGFPlow(light grey columns) and HUES9-CAG-EGFPhigh 
cells (dark grey columns), sorted at day 10 (D10 sort) or day 12 (D12 sort) of 
differentiation. (B): QPCR analysis of the mRNA expression of SOX1, PAX6 and AFP 
in HUES9-CAG-EGFPlow (light grey columns) and HUES9-CAG-EGFPhigh cells (dark 
grey columns), sorted at day 10 (D10 sort) or day 12 (D12 sort) of differentiation. (C) 
QPCR analysis of the mRNA expression of OCT4 and NANOG in HUES9-CAG-
EGFPlow and HUES9-CAG-EGFPhigh cells, sorted at day 10 (D10 sort) or day 12 (D12 
sort) of differentiation. Levels of significance were calculated by the Student T-test; *: 
p<0.05, n=3. The image is taken from Szebényi et al.123, with some modifications. 
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Figure 19. Analysis of directed differentiation of BG01V-CAG-EGFP hESCs. (A) 
Flow cytometry analysis of the pluripotency marker SSEA4 and CAG-EGFP on cells 
from whole BG01V-CAG-EGFP EBs at different stages of differentiation. Dot plot 
quadrant gates are set based on IgG3 isotype control for SSEA4 and EGFP fluorescence 
intensity of the undifferentiated BG01V-CAG-EGFP cells for CAG-EGFP. (B) QPCR 
analysis of cardiac lineage markers (ISL1, NKX2.5, ALCAM and TNNT2), the ectoderm 
marker SOX1 and the early endoderm marker AFP in HUES9-CAG-EGFPlow and 
HUES9-CAG-EGFPhigh cells sorted at day 12 of differentiation. The image is taken 
from Szebényi et al.123, with some modifications. 
 
To further confirm the ability of the CAG-EGFP system to identify cardiac 
progenitors, BG01V-CAG-EGFP hESCs were differentiated with the same directed 
differentiation protocol as used for differentiation of HUES9-CAG-EGFP cells (see 
Figure 13). BG01V-CAG-EGFP cells also started to form a CAG-EGFPhigh 
subpopulation, however two days later than HUES9-CAG-EGFP cells (Figure 19A). 
This delay was presumably caused by an inherent feature of the BG01V hESC line, 
since this cell line was established from an embryo with Down syndrome causing 
congenital heart failure 124, 125. Distribution of cardiac-specific mRNA levels between 
the two fractions sorted on day 12 were similar to that observed in the case of HUES9-
CAG-EGFP cells (Figure 19B), since ISL1, ALCAM and TNNT2 transcription levels 
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were higher in BG01V-CAG-EGFPhigh samples, while NKX2.5, and the non-cardiac 
specific genes showed higher expression in BG01V-CAG-EGFPlow cells. 
 
5.3.2. Comparing CAG-EGFP-based isolation of cardiac progenitors to other methods 
known from the literature   
In good agreement with the increase of ALCAM transcription in D12 CAG-
EGFPhigh samples (see Figure 18A),  CAG-EGFPhigh cells started to express ALCAM at 
the protein level on day 12 of the differentiation (Figure 20A, black arrows indicate 
ALCAMpos/CAG-EGFPhigh cells). However, a clear co-expression of the two markers 
was first observed on day 14. The ability of ALCAM to identify solely cardiomyocytes 
is stage specific and it has not been indicated that ALCAM is suitable for the 
identification of cardiac progenitors; therefore it could be assumed that on day 12 CAG-
EGFPhigh cells identify CPCs that are becoming ALCAM positive CMs by day 14. 
To further evaluate this possibility, half of the single cell suspension obtained by 
trypsinization from EBs was sorted into ALCAM positive (ALCAMpos) and ALCAM 
negative (ALCAMneg) fractions (Figure 20A), while the other half into CAG-EGFPhigh 
and CAG-EGFPlow fractions (as shown in Figure 17). On day 12 TNNT2 and NKX2.5 
transcriptional levels did not differ significantly between ALCAMpos and ALCAMneg 
samples, while by day 14 TNNT2 transcriptional levels of the ALCAMpos and 
ALCAMneg fractions became more distinct through a three-fold increase of TNNT2 
expression in the ALCAMpos sample (Figure 20B). By day 14, the ALCAMpos and 
ALCAMneg populations became more distinct based on their NKX2.5 transcriptional 
levels as well, however the ALCAMneg fraction expressed a similar level of NKX2.5 
transcripts than the CAG-EGFPlow fraction, while CAG-EGFPhigh cells expressed 
significantly lower levels of NKX2.5 than all the other samples, irrespectively of the day 
of sorting. All these findings outlined that early cardiomyocytes expressed ALCAM on 
day 14, while a subpopulation of ALCAMpos cells marked by the CAG-EGFP system 
expressed TNNT2, but only low levels of NKX2.5.  
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Figure 20. Analysis of the cardiac progenitors obtained by the CAG-EGFP 
separation system and those by the presence of CD166. (A): HUES9-CAG-EGFP 
EBs were sorted based on their CD166/ALCAM expression intensities into CD166 
negative (CD166neg) and positive (CD166pos) fractions on day 12 (D12) and day 14 
(D14) of the differentiation. Black arrows indicate ALCAMpos/CAG-EGFPhigh cells. 
(B): QPCR analysis of the mRNA expression of TNNT2 and NKX2.5 in the different 
subpopulations (GFP sort: HUES9-CAG-EGFPlow and HUES9-CAG-EGFPhigh cells; 
CD166 sort: CD166neg and CD166pos cells) sorted either at day 12 (left panel) or day 14 
(right panel) of differentiation. Levels of significance were calculated by the Student T-
test; *: p<0.05, n=3. The image is taken from Szebényi et al.123. 
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Figure 21. Comparison of the CAG-EGFP system with early cardiomyocyte 
markers SIRPA and VCAM1. (A) Flow cytometry analysis of SIRPA and CAG-
EGFP in HUES9-CAG-EGFP EBs at day 10 (D10), day 12 (D12) and day 14 (D14) of 
differentiation. (B) Flow cytometry analysis of SIRPA and VCAM1 in HUES9-CAG-
EGFP EBs at day 10 (D10), day 12 (D12) and day 14 (D14) of differentiation. Dot plot 
quadrant gates are set based on the background levels of fluorescence of Goat Anti-
Mouse Alexa Fluor 647 (GAM-AF647) for SIRPA and IgG1kappa isotype control for 
VCAM1. Black coloured dots indicate CAG-EGFPhigh cells. The image is taken from 
Szebényi et al.123. 
 
To further investigate CPCs (D12 cells) and early cardiomyocytes (D14 cells) 
identified by their high CAG-EGFP expression intensity, SIRPA and VCAM1 
expression was investigated between day 10, the emergence of the CAG-EGFPhigh 
subpopulation and day 14, the emergence of ALCAMpos/CAG-EGFPhigh early 
cardiomyocytes (Figure 21). CAG-EGFPhigh cells started to express SIRPA on day 12 
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(28.69% of the CAG-EGFPhigh cells were SIRPApos), and by day 14 58.09% were 
SIRPApos, further supporting that the CAG-EGFPhigh population contains early 
cardiomyocytes (Figure 21A). As it was reported previously88, expression of VCAM1 
only partially overlapped with SIRPA, and accordingly to this approximately 36% of 
CAG-EGFPhigh cells (indicated by black dots on Figure 21B) expressing SIRPA 
expressed VCAM1 by day 14.  
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5.4. Examining different culture conditions for isolated CAG-EGFPhigh cardiac 
progenitors  
To further investigate CAG-EGFPhigh cells, culture conditions needed to be 
tested allowing re-culture and differentiation of the isolated cells. First, a cell line has 
been established by mechanically removing and enzymatically dissecting a contracting 
area and the surrounding tissues from a HUES9 (EGFP negative) differentiation culture. 
The dissected cells were re-cultured in DM and underwent several passages to generate 
a feeder cell line with fibroblast morphology, possibly able to support cardiac 
differentiation. The cell line was termed as cardiomyocyte supporting cells (CMSCs) 
and exhibited a mesenchymal stem cell-like phenotype126, 127, since FACS 
measurements confirmed that CMSCs were positive for CD44, CD73, CD105, CD90, 
CD166 (ALCAM) and negative for CD45, CD34, CD31, CD56, CD61, SSEA4, 
respectively (Figure 22).  
 
Figure 22. Characterization of the CMSC line established from a contracting area 
of a HUES9 differentiation culture. Green: CD105-FITC, CD44-FITC, CD56-FITC, 
CD61-FITC; orange: CD45-PE, CD31-PE, CD73-PE; red: CD90-APC, SSEA4-APC, 
CD166-AlexaFluor647, CD34-APC (from left to right). Blue lines indicate the signal of 
the isotype controls. The image is going to be published in Szebényi et al. (manuscript 
in preparation). 
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Figure 23. Comparison of different culture conditions for supporting cardiac 
differentiation of HUES9-CAG-EGFPhigh cells. (A) Schematic outline of the different 
culture conditions applied. (B) Representative images of HUES9-CAG-EGFPhigh cells 
under different culture conditions 3 and 18 days after sorting. Scale bars represent 200 
µm. (C) QPCR analysis of the cardiac gene TNNT2 in samples cultured for 18 days after 
sorting. The sorting was performed on day 12 of the differentiation. The unsorted 
sample was collected on day 30 of the differentiation. CPCs: cardiac progenitor cells; 
D: day; M: medium; rEBs: reaggregated embryoid bodies; DM: differentiation medium; 
RCM: ReproCardio medium; Gel: gelatin; CMSC: cardiomyocyte supporting cells. The 
image is going to be published in Szebényi et al. (manuscript in preparation). 
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Next, two different monolayers and a 3D suspension culture were tested in 
combination with two different culture media to compare their ability for supporting 
cardiac differentiation of CAG-EGFPhigh cells (Figure 23A). HUES9-CAG-EGFPhigh 
cells were isolated on day 12 and replated either in round bottom 96 well suspension 
(HydroCell) plates to form 3D aggregates or were cultured as monolayers on gelatine or 
on a layer of CMSCs (Figure 23B). Gelatine was tested based on previous reports, 
providing evidence for that gelatine-coated surfaces are able to support cardiac 
differentiation128, 129. In addition, the routinely used differentiation medium (DM) was 
compared to ReproCardio medium (RCM), under all of these above mentioned 
circumstances. RCM was tested because this medium is specially offered for culturing 
cardiomyocytes, hence it could be assumed that this medium would provide some 
benefit for cardiac progenitors as well.  
CAG-EGFPhigh cells cultured as monolayers exhibited mesenchymal 
morphology and were able to divide, demonstrated by the increased confluency of the 
cells after 18 days in culture (Figure 23B). Growth of reaggregated EBs (rEBs) was 
modest and at this time point was not further investigated (for detailed investigation of 
growth of rEBs see Chapter 6).  
Samples were collected into TRIzol Reagent after 18 days of culture and TNNT2 
mRNA levels were compared by QPCR to evaluate the most potent culture condition in 
terms of cardiomyocyte differentiation efficiency (Figure 23C). Increased levels of 
TNNT2 transcription could only be detected in the case of the 3D aggregates, while 
RCM did not show any advantages over the traditional DM in supporting cardiac 
differentiation of the isolated HUES9-CAG-EGFPhigh cells.  
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5.5. CAG-EGFPhigh cardiac progenitors give rise to a relative pure population of 
cardiomyocytes  
In order to further examine the potential of the CAG-EGFPhigh cells, isolated 
CAG-EGFPhigh and CAG-EGFPlow cells were plated in suspension cultures either on day 
10 or day 12, and maintained as rEBs for several weeks in the presence of 10% bovine 
serum. Spontaneous contractile activity was first detected at 25 days after the formation 
of CAG-EGFPhigh rEBs (approx. 30% of CAG-EGFPhigh rEBs contracted; see 
Supplementary video 2). CAG-EGFPlow rEBs did not show any contractile activity. 
Figure 24 shows that after 30 days in culture CAG-EGFPhigh rEBs expressed 
significantly higher levels of TNNT2 and NKX2.5 than CAG-EGFPlow rEBs, and these 
transcriptional levels were several fold higher than those of the initially isolated CAG-
EGFPhigh cells (D10 CAG-EGFPhigh and D12 CAG-EGFPhigh), implying maturation of 
the CPCs into CMs.  
 
 
Figure 24. QPCR analysis of cardiac specific genes NKX2.5 and TNNT2. HUES9-
CAG-EGFPlow (light grey) and HUES9-CAG-EGFPhigh (dark grey) cells were sorted 
either on day 10 (D10) or day 12 (D12) of differentiation and differentiated an 
additional 30 days long (D10+30 and D12+30 samples, respectively). Levels of 
significance were calculated by the Student T-test; *: p<0.05, n=6. The image is taken 
from Szebényi et al.123. 
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Figure 25. Immunocytochemical analysis of ectoderm and endoderm markers in 10 
days old HUES9-CAG-EGFPlow and HUES9-CAG-EGFPhigh rEBs. (A) Red: Anti-
Neuron-specific beta-III Tubulin (βIII-Tub). (B) Red: the early endoderm marker Anti-
alpha-Fetoprotein (AFP). The rEBs were generated from cells sorted on day 12 of the 
differentiation. Green: CAG-EGFP. Blue: DAPI. The image is taken from Szebényi et 
al.123. 
 
In order to examine the cell types present in the rEBs, immunocytochemistry 
analysis of the neuronal marker βIII Tubulin, the early endoderm marker AFP, the 
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endothelial cell marker PECAM, the smooth muscle cell marker SMA, as well as the 
cardiomyocyte marker troponin I was carried out on rEBs generated from D12 CAG-
EGFPhigh or CAG-EGFPlow cells (Figure 25-27). For immunostaining floating rEBs 
were seeded on confocal microscopy chambers, additionally CAG-EGFPhigh rEBs 
needed a short trypsinization to achieve better adhesion.  
 
 
Figure 26. Cardiac troponin I (cTnI) immunostaining of 10 day-old HUES9-CAG-
EGFPlow and HUES9-CAG-EGFPhigh rEBs. The rEBs were generated from cells 
sorted on day 12 of the differentiation. Green: CAG-EGFP. Red: Anti-Human Cardiac 
Troponin I (cTnI). Blue: DAPI.  The image is taken from Szebényi et al.123. 
 
In CAG-EGFPlow rEBs an appreciable amount of neuronal committed cells with 
high βIII Tubulin expression could be detected, while CAG-EGFPhigh rEBs did not 
stained for βIII Tubulin (Figure 25A). AFP positive cells were detected in all rEBs 
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examined, however the extremely low yield showed that endoderm differentiation was 
not supported by the applied directed differentiation protocol (Figure 25B). Troponin I 
was only expressed in CAG-EGFPhigh rEBs (Figure 26A) and in cells around them 
(Figure 26B), while cells around the rEBs often stained positive for SMA in both types 
of rEBs (Figure 27A). PECAM positive endothelial cells could not be found in either of 
the rEBs (Figure 27B).  
 
 
Figure 27. Immunocytochemical analysis of cardiovascular markers in 10 days old 
HUES9-CAG-EGFPlow and HUES9-CAG-EGFPhigh rEBs. (A) Red: Anti-Alpha-
Smooth Muscle Actin (SMA). (B) Red: Anti-Human Platelet endothelial cell adhesion 
molecule (PECAM). The rEBs were generated from cells sorted on day 12 of the 
differentiation. Green: CAG-EGFP. Blue: DAPI. The image is taken from Szebényi et 
al.123, with some modifications. 
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Intracellular staining against Toponin I was detected by FACS and it was 
confirmed that more than 98% of the cells of CAG-EGFPhigh rEBs were 
cardiomyocytes, indicating that approximately 2% of the cells present in CAG-EGFPhigh 
rEBs are smooth muscle cells (Figure 28).  
 
 
Figure 28. Flow cytometry analysis of cardiac troponin I (cTnI) expression on 20-
day old HUES9-CAG-EGFPhigh rEBs. The rEBs were generated from cells sorted on 
day 12 of the differentiation. Dot plot quadrant gate for cTnI (right panel) is set based 
on IgG2a isotype control (left panel), while the gate for EGFP fluorescence is set based 
on the fluorescence intensity of fixed undifferentiated CAG-EGFP cells. The image is 
taken from Szebényi et al. 123. 
 
In order to determine the cardiac cell subtypes in present in CAG-EGFPhigh 
rEBs, transcriptional levels of MYL2, a marker of ventricular CMs, MYL7, the marker 
of atrial CMs and HCN4, the earliest expressed nodal cell marker were analysed by 
QPCR (Figure 29). HCN4 and MYL2 were expressed at very low levels, whereas 
MYL7 showed high level expression in CAG-EGFPhigh rEBs, indicating that 
cardiomyocytes derived from the isolated CAG-EGFPhigh cells are mostly of atrial type. 
This observation may indicate a differential regulation of the CAG driven expression of 
EGFP in various CM types. This finding is further supported by one of the previous 
observation regarding the presence of troponin I positive areas with lower EGFP signal 
in the spontaneous differentiation cultures (see Figure 11). 
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Figure 29. QPCR analysis of the mRNA expression of HCN4, MYL2, and MYL7 in 
HUES9-CAG-EGFPhigh rEBs, generated from cells sorted on day 12 of 
differentiation. Levels of significance were calculated by the Student T-test; *: p<0.05, 
n=3.The image is taken from Szebényi et al.123. 
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5.6. Enhanced culture conditions for supporting the growth of CAG-EGFPhigh rEBs 
without losing cardiac commitment 
5.6.1. Modest growth of 3D aggregates generated from isolated CAG-EGFPhigh cells   
Next, the ability of CAG-EGFPhigh rEBs to grow was investigated by 
fluorescence imaging (Figure 30) and fluorescence plate reader measurements (Figure 
31). Figure 30 shows representative images of rEBs 3 and 20 days after isolation of 
CAG-EGFPhigh (Figure 30A) and CAG-EGFPlow (Figure 30B) cells on day 10 and day 
12, respectively. Fluorescent microscopy data suggested, that CAG-EGFPhigh cells 
sorted on day 10 exhibited slightly better aggregation and/or proliferation properties 
than the cells isolated on day 12, since CAG-EGFPhigh rEBs generated from cells 
isolated on day 12 (D12 CAG-EGFPhigh rEBs) were slightly smaller at the end of the 
differentiation than those generated from cells isolated on day 10 (D10 CAG-EGFPhigh 
rEBs) (Figure 30A). Additionally, several differences between CAG-EGFPhigh and 
CAG-EGFPlow rEBs were observed, for example in the ability to grow and in their 
shape as well, since CAG-EGFPlow cells formed perfect spheroids (while CAG-
EGFPhigh rEBS were more spindle-shaped) and exhibited higher proliferation capacity 
resulting larger rEBs (Figure 30B).   
 
Figure 30. Representative fluorescent images of reaggregated embryoid bodies 
(rEBs) 3 and 20 days after sorting. (A) HUES9-CAG-EGFPhigh rEBs and (B) HUES9-
CAG-EGFPlow rEBs. The cells were either sorted on day 10 (D10 sort) or day 12 (D12 
sort) of the differentiation. EGFP expression was detected by fluorescence microscopy.  
The image is taken from Szebényi et al.123. 
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In order to allow better quantification of the growth of CAG-EGFPhigh rEBs, 
fluorescence plate reader measurements were performed 3 and 20 days after cell sorting 
(Figure 31). Plate reader measurements were carried out to detect fluorescence of either 
the CAG-EGFP signal (Figure 31A) or that of the propidium iodide (PI) staining of 
fixed rEBs (Figure 31B). Both methods confirmed the growth of rEBs during 20-day-
long culture, additionally the PI staining-based method provided evidence about 
modest, but significant growth of the rEBs (Figure 31B). Fluorescence intensities of the 
PI staining of 3 day old rEBs sorted on day 10 (D10 sort) and day 12 (D12 sort) were 
similar, corresponding to the identical number of cells seeded on the wells three days 
before the measurement (30,000 cells/well) and suggesting similar reaggregation 
properties among CAG-EGFPhigh cells sorted either on day 10 or day 12.      
  
 
Figure 31. Quantification of the growth of CAG-EGFPhigh reaggregated embryoid 
bodies (rEBs). (A) Fluorescence intensity of HUES9-CAG-EGFPhigh rEBs measured by 
fluorescence plate reader 3 and 20 days after sorting. (B) Fluorescence intensity of 
propidium iodide staining in HUES9-CAG-EGFPhigh rEBs measured by fluorescence 
plate reader 3 and 20 days after sorting. Sorting was performed either on day 10 (D10 
sort) or day 12 (D12 sort) of differentiation. Levels of significance were calculated by 
the Student T-test; *: p<0.05, n=6. The image is taken from Szebényi et al.123. 
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5.6.2. Thiazovivin enhances reaggregation and survival of the sorted cells 
Reaggregation properties of isolated cells were relatively poor, since one day 
after the sorting procedure a large amount of single cells was detectable, floating around 
the forming CAG-EGFPhigh rEBs (Figure 32, Differentiation Medium panel, upper left 
image). To enhance survival and reaggregation ability of CAG-EGFPhigh cells, culture 
conditions were optimized.  
 
 
Figure 32. Representative images of HUES9-CAG-EGFPhigh reaggregated 
embryoid bodies (rEBs) 1 and 18 days after sorting, cultured either in 
differentiation or in END-2 conditioned medium. The rEBs were generated from 
cells sorted on day 12 of the differentiation. Tzv: thiazovivin. „+”: with treatment. „-”: 
without treatment. Scale bars represent 500 µm. The image is going to be published in 
Szebényi et al. (manuscript in preparation). 
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Isolated CAG-EGFPhigh cells were plated in HydroCell 96 well plates either in 
DM or in END2-CM, and in the absence or presence of Thiazovivin (Figure 32). 
Thiazovivin is a cell permeable small molecule, able to reduce apoptosis and support 
single cell survival of hESCs after enzymatic dissociation, through stabilizing E-
cadherin and inhibiting Rho-associated kinase (ROCK) activity130. A similar ROCK 
inhibitor, Y-27632 was reported to improve survival of hESC-derived cardiomyocytes 
after enzymatic dissociation131, therefore Thiazovivin seemed to be an interesting 
candidate for optimization studies aiming to improve reaggregation and survival 
properties of the isolated CAG-EGFPhigh cells after sorting.  
Isolated cells were treated with 2 µM Thiazovivin right after the sorting 
procedure to promote cell survival during reaggregation. After 24 hours clear 
differences could be observed between control and Thiazovivin treated wells, as well as 
between rEBs cultured in DM or in END2-CM (Figure 32). In END2-CM CAG-
EGFPhigh cells showed enhanced reaggregation compared to cells recultured in DM, 
while treatment with Thiazovivin further reduced the amount of free-floating cells in 
END2-CM. The effect of Thiazovivin was also observable in the case of CAG-EGFPhigh 
cells replated in DM. 
 
 
Figure 33. Comparison of the effect of different culture conditions on the 
survival of HUES9-CAG-EGFPhigh cells after sorting. Cell number was counted by 
trypan blue staining of trypsinized HUES9-CAG-EGFPhigh reaggregated embryoid 
bodies one day after sort. The rEBs were generated from cells sorted on day 12 of the 
differentiation. The image is going to be published in Szebényi et al. (manuscript in 
preparation). 
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To quantify the observed effects cell counting by Trypan Blue was used after 
enzymatic dissociation of some of the newly formed rEBs (n=3) (Figure 33). This 
method was chosen instead of the previously applied detection of PI staining of fixed 
rEBs, because after fixation PI staining was not feasible for distinguishing between 
living and dead cells, while the PI staining of living rEBs and floating cells around it 
could not be distinguished from the background signal of PI. The trypan blue staining 
showed that enhanced aggregation properties were coupled to increased survival of the 
sorted cells (Figure 33). The first medium change was carried out two days after sort 
and this resulted in the final clearing of wells from free-floating cells in every culture 
condition tested. 
After 18 days in culture, the size of the rEBs  were found to be more increased in 
END2-CM, than in DM; this was confirmed by light microscopy (Figure 32) and by 
plate reader measurements detecting the CAG-EGFP signal (Figure 34). Enhanced 
survival and reaggregation properties provided by Thiazovivin treatment resulted in 
further size increase of CAG-EGFPhigh rEBs (Figure 32 and 34). 
 
 
Figure 34. Comparison of the effect of different culture conditions on the growth of  
HUES9-CAG-EGFPhigh reaggregated embryoid bodies (rEBs). Fluorescence plate 
reader measurement of the fluorescence intensity of HUES9-CAG-EGFPhigh rEBs after 
18 days in culture either in differentiation or END-2 conditioned medium. The rEBs 
were generated from cells sorted on day 12 of the differentiation. Tzv-: thiazovivin 
treatment was not applied. Tzv+: thiazovivin treatment was applied. The image is going 
to be published in Szebényi et al. (manuscript in preparation). 
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However, TNNT2 and Phospholamban (PLN) transcription levels were lower in 
rEBs cultured in END2-CM than in DM, regardless of Thiazovivin treatment, 
suggesting that non-CM derivatives of the CPCs overgrow cardiomyocytes during the 
culture period (Figure 35). Since previous data suggest (see Szebényi et al. and Figure 
27) that CAG-EGFPhigh CPCs are able to give rise to SMA positive, but not to PECAM 
positive cells, it can be assumed that these non-CM derivatives are presumably smooth 
muscle cells. Regardless of the type of the non-CM population, aim of the further 
studies was to promote cardiomyocyte differentiation under the END2-CM+Tzv culture 
condition (allowing the most growth of rEBs) to increase the cardiomyocyte yield of the 
initial method (CAG-EGFPhigh rEBs cultured in DM). 
 
 
Figure 35. QPCR analysis of cardiac specific genes TNNT2 and PLN. HUES9-CAG-
EGFPhigh reaggregated embryoid bodies (rEBs) were cultured either in differentiation 
medium (DM) or in END-2 conditioned medium (END2-CM) for 18 days. The rEBs 
were generated from cells sorted on day 12 of the differentiation. The unsorted sample 
was collected on day 30 of the differentiation. Tzv: thiazovivin. The image is going to 
be published in Szebényi et al. (manuscript in preparation). 
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5.6.3. Isoproterenol enhances cardiac differentiation of CAG-EGFPhigh cells cultured in 
END-2 conditioned medium 
As discussed in the Introduction, the addition of exogenous NRG-1β, a 
cardioactive growth factor resulted in enhanced generation of ventricular CMs84 and 
induced proliferation of mononucleated CMs in vivo82. NRG-1β acts on ErbB4, a 
tyrosine kinase receptor required for normal cardiac differentiation during embryonic 
development132. Therefore NRG-1β was tested to enhance cardiomyocyte 
differentiation of CAG-EGFPhigh CPCs in END2-CM, after Thiazovivin treatment.  
Besides of NRG-1β, Isoproterenol treatment was also tested. Isoproterenol is a 
β1- and β2-adrenoreceptor (AR) agonist and structurally similar to adrenaline. 
Isoproterenol can possess arrhythmogenic effects on hESC-CMs 133 and can cause 
cellular hypertrophy or apoptotic cell death through the β1-AR subtype, whereas 
stimulation of the β2-AR inhibits apoptosis134-136. It was suggested in the case of a rat 
myoblast cell line (H9c2), often used in toxicological studies, that undifferentiated 
myoblasts are less prone to the cardiotoxic effect of Isoproterenol than CMs 
differentiated from them137. The idea that cardiac precursors and mature CMs react 
diversely on β-adrenergic stimulation is further supported by Khan et al., demonstrating 
that survival and proliferation of mouse and human CPCs derived from the heart is 
promoted by adrenerg stimuli through β2-AR, while further maturation leads to 
significant β1-AR expression and thereby to sensitization to isoproterenol-induced cell 
death138. Moreover, Yan et al. demonstrated that β-adrenergic stimulation with 10 µM 
Isoproterenol during differentiation of mouse ESCs significantly enhances the 
cardiomyocyte yield139. All these data suggested that Isoproterenol might have the 
ability to enhance the cardiomyocyte yield of CAG-EGFPhigh CPCs when differentiated 
in END2-CM, after Thiazovivin treatment.  
NRG-1β was used with 100 ng/ml final concentration (Nrg), based on the work 
of Zhu et al. applying NRG-1β during hESC differentiation 84, while Isoproterenol was 
used with 10 µM final concentration (Iso). The first treatment was applied two days 
after sorting, and during the following 12 days the treatment was repeated in every third 
day when the medium was changed. After 18 days in culture, the size of CAG-EGFPhigh 
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rEBs were found to be similar, irrespective of whether the rEBs were cultured under 
treated (END2-CM+Tzv+Nrg and END2-CM+Tzv+Iso) or control (END2-CM+Tzv) 
conditions (Figure 36A). This finding was also confirmed by plate reader 
measurements detecting the CAG-EGFP signal (Figure 36B). While the treatments did 
not modify the ability of rEBs to grow, enhanced transcription of TNNT2 demonstrated 
that CM-differentiation abilities increased in Isoproterenol treated rEBs  (Figure 36C). 
The TNNT2 transcript level measured in rEBs cultured in END2-CM and treated with 
Thiazovivin and Isoproterenol was similar to that of rEBs cultured in DM (Figure 35). 
NRG-1β failed to achieve increased cardiomyocyte differentiation, moreover, it seemed 
that NRG-1β decreased cardiomyocyte generation efficiency (Figure 36C).  
 
 
Figure 36. The effect of Neuregulin (Nrg) and Isoproterenol (Iso) on HUES9-CAG-
EGFPhigh reaggregated embryoid bodies (rEBs) cultured in END-2 conditioned 
medium (END2-CM) for 18 days. (A) Representative images of HUES9-CAG-
EGFPhigh rEBs cultured under different culture conditions. (B) Fluorescence plate reader 
measurement of the fluorescence intensity of HUES9-CAG-EGFPhigh rEBs cultured 
under different culture conditions. (C) QPCR analysis of the cardiac specific gene 
TNNT2 in HUES9-CAG-EGFPhigh rEBs cultured under different culture conditions. The 
rEBs were generated from cells sorted on day 12 of the differentiation. Tzv: thiazovivin. 
The image is going to be published in Szebényi et al. (manuscript in preparation). 
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6. Discussion 
The promise of human embryonic and induced pluripotent stem cells providing 
an inexhaustible source of human cardiomyocytes for medical applications was initially 
limited by inefficient differentiation protocols (resulting in low cardiomyocyte yield), 
lack of methods for purification of living cardiomyocytes, and the immature state of the 
derived CMs. Our research group joined the field of stem cell biology with the aim to 
address the generation of large amounts of pure cardiomyocytes and progenitors of the 
cardiac lineage.  
In the last decade several transgenic reporter systems have been established, 
allowing the identification and selection of cardiomyocytes and precursors of the 
cardiac lineage148. This effort was motivated by the lack of known cell surface markers 
allowing the isolation of cardiomyocytes (and cardiac progenitors) without the 
disruption of their cell membranes. However, most of these studies described cardiac-
specific promoter based reporter hESC lines, where the stable integration of the 
transgene could only be detected when the hESCs differentiated into the cardiac 
lineage148. Our research group established a “double feature” system, allowing the 
detection and isolation of transgene expressing hESCs (Figure 5 and 6) and their 
cardiomyocyte progeny (Figure 9 and 10) based on the CAG promoter driven EGFP 
expression.  
The original CAG promoter is an artificial promoter constructed from the CMV 
enhancer, the chicken β-actin and the rabbit β1-globin sequences, while the version 
used here contains a CMV enhancer region, two sequences from the chicken β-actin 
promoter and one short part of the rabbit β1-globin promoter90. The cardiac reporter 
feature is presumably a specific property of the variant of the CAG promoter that was 
used90, resulting in that CAG-EGFP expressing hESCs giving rise to cardiomyocytes 
with exceptionally high EGFP signal (Figure 9).  
 Next, we verified the CAG-EGFP system for allowing the identification of 
cardiac progenitors by monitoring the emergence and fate of CAG-EGFPhigh cells 
during differentiation (Figure 12 and 16) and by QPCR analysis of sorted CAG-
EGFPhigh cells (Figure 18 and 19).  We confirmed by QPCR (Figure 24 and 29), 
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immunocytochemical analysis (Figure 25-27) and by flow cytometry measurements 
(Figure 28) that the isolated CAG-EGFPhigh cells mostly give rise to cardiomyocytes 
when cultured as 3D aggregates (Figure 23). These findings were also supported by the 
observed spontaneous contraction in 30% of the CAG-EGFPhigh rEBs.  
 It is important to emphasize that a key step during our work was to recognize the 
need to set up a cardiac-directed differentiation protocol (Figure 13). The use of the 
directed differentiation protocol allowed us to enrich for cardiac progenitors (Figure 
14), thereby not only the amount, but also the sorting purity of CAG-EGFPhigh cells 
could be enhanced. Directed differentiation synchronized and hastened the 
differentiation of individual cells (SSEA4 expression declined earlier than during 
spontaneous differentiation, see Figure 14A), hence contamination of the CAG-
EGFPhigh population by SSEA4 positive cells could be avoided already on day 10 of the 
differentiation (Figure 16). This was important because some of the undifferentiated 
cells possessed similar CAG-EGFP signal intensity than CAG-EGFPhigh CPCs (Figure 
16 and 19A).  
To identify the maturity status of CAG-EGFPhigh CPCs, we compared the CAG-
EGFP system to recently discovered cardiomyocyte- and cardiac precursor cell surface 
markers such as SIRPA and VCAM1. Comparison of different systems is always 
difficult due to variation in differentiation capabilities of hESC lines 125and due to 
differences in the kinetics of the differentiation caused by the variety of differentiation 
protocols applied. In addition, these cell surface marker-based systems show some 
leakiness, since according to the original articles 17.2% of the SIRPA negative cells are 
also troponin T positive86, while 25.8% of troponin T positive cells are VCAM1 
negative 118 at around the time when the beating activity starts (day 9). Still, sorting 
based on SIRPA expression on day 8 or on VCAM1 expression on day 11 resulted pure 
population of CMs according to these articles. The relation between SIRPA and 
VCAM1 positive cells was also extensively studied and it was shown that SIRPApos 
cells give rise to the VCAM1pos/SIRPApos population88, 117. 
Based on our findings, CAG-EGFPhigh cells emerge earlier (on day 10) than 
SIRPA positive cells (around day 12), however, these two population overlapped 
partially already on day 12, while on day 14 the majority of CAG-EGFPhigh cells 
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expressed SIRPA (Figure 21A). Moreover, one third of SIRPA positive CAG-EGFPhigh 
cells already expressed VCAM1 at this time point (Figure 21B). These findings also 
supported our previous findings regarding the identity of CAG-EGFPhigh cells as 
progenitors of the cardiac lineage and suggested a less mature progenitor state for CAG-
EGFPhigh CPCs than represented by SIRPApos cardiac precursor cells. 
 The directed differentiation kinetics of HUES9-CAG-EGFP cells differs from 
that of shown by Dubois et al., since in our system SIRPA expression upregulates on 
day 12 (day 7 in Dubois et al) and spontaneous contractile activity starts around day 14 
(day 9 in Dubois et al.). Accordingly, emergence of SIRPA positive cells precedes the 
onset of spontaneous contractile activity by two days in both systems. Therefore, we 
assumed that day 12 conditions in our system might be most comparable to day 7 
conditions documented by Dubois et al.86.  
Dubois et al. reported 86 that on day 8 of differentiation only half of the SIRPA 
positive cells were NKX2.5-GFP positive, while at the same time, 98% of the SIRPA 
positive cells expressed cTnT. This means that at this stage (one day before the 
contractile activity onsets) there is a SIRPApos/cTnTpos/NKX2.5neg subpopulation in the 
differentiation culture. In accordance with this finding, day 12 CAG-EGFPhigh cells 
showed upregulated TNNT2 transcription and low levels of NKX2.5 transcripts (Figure 
18A and Figure 20B), while some of the CAG-EGFPhigh cells already expressed SIRPA 
on day 12 (Figure 21A). By day 14 SIRPA expression became even more characteristic 
for the CAG-EGPFhigh population (Figure 21A), while NKX2.5 transcription levels 
remained low (Figure 20C).  
The expression of ALCAM was also monitored during the differentiation of 
HUES9-CAG-EGFP hESCs (Figure 14A and 20A). We found that the majority of 
CAG-EGFPhigh cells became ALCAM positive by day 14, while on day 12 the ratio of 
ALCAM positive to negative cells was only slightly higher in the CAG-EGFPhigh than 
in the CAG-EGFPlow population (Figure 20A), still resulting in a significant difference 
of their ALCAM mRNA levels (Figure 18A). However, we did not expect a clear 
separation between day 12 ALCAMneg and ALCAMpos samples regarding TNNT2 or 
NKX2.5 transcription levels (Figure 20B and C), since the ALCAM protein is a stage-
specific marker of cardiomyocytes, and does not allow the specific identification of 
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cardiac progenitors. At the same time, on day 12, the CAG-EGFP system already 
provided excellent separation, demonstrated by the significantly higher TNNT2 
transcription level of the CAG-EGFPhigh sample compared to the CAG-EGFPlow sample 
(Figure 18A and 20B).  
Expression of ALCAM on day 14 CAG-EGFPlow cells has to be discussed more 
thoroughly, since it can be interpreted in two different ways: 1) the CAG-
EGFPlow/ALCAMpos subpopulation represents CMs (CAG-EGFPlow cells can also give 
rise to CMs, see Figure 11) or 2) ALCAM does not allow the identification of CMs in 
our system. The second possibility could be excluded based on the QPCR analysis of 
samples sorted on day 14, showing elevated levels of TNNT2 transcripts in ALCAMpos 
compared to ALCAMneg samples (Figure 20B). Interestingly, the day 14 ALCAMpos 
sample showed only a slightly lower level of TNNT2 mRNA, than the CAG-EGFPhigh 
sample. This finding, on one hand, can suggests that not only the CAG-
EGFPhigh/ALCAMpos cells, but the majority of CAG-EGFPlow/ALCAMpos and CAG-
EGFPneg/ALCAMpos cells are CMs by day 14, but can also refer to a less pure 
ALCAMpos population containing proportionally more mature CMs (expressing higher 
levels of TNNT2 mRNA) than the CAG-EGFPhigh fraction (possibly containing 
proportionally more immature CMs).  
A key issue was to interpret the data obtained by the QPCR analysis about 
NKX2.5 expression. NKX2.5 mRNA level of ALCAMpos and ALCAMneg samples were 
similar to that of the CAG-EGFPlow sample, and was significantly higher than observed 
in the CAG-EGFPhigh fraction both in day 12 and in day 14 experiments (Figure 20C). 
These results were especially contradictory in the case of day 14 samples, when the 
QPCR analysis of TNNT2 mRNA showed elevated expression both in ALCAMpos and 
in CAG-EGFPhigh samples compared to ALCAMneg and CAG-EGFPlow samples, 
respectively (Figure 20B). We assumed that a pure ALCAMpos population containing 
mostly CMs of a particular phenotype would have resulted in significant differences in 
distribution of NKX2.5 mRNA levels between the ALCAMneg and ALCAMpos sample. 
However, this was not the case, therefore we concluded that the ALCAMpos population 
has to contain ALCAMpos/NKX2.5high cells to compensate for the significantly low 
NKX2.5 levels of CAG-EGFPhigh cells (a subpopulation of the ALCAMpos fraction), 
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resulting in a lowered average NKX2.5 mRNA level of the ALCAMpos sample. The 
ALCAMpos/NKX2.5high phenotype can represent a more mature stage of CM 
differentiation, since day 12 CAG-EGFPhigh CPCs expressing NKX2.5 mRNA at low 
levels are also able to give rise to NKX2.5high CMs (Figure 24). 
However, these results, together with the fact that the CAG-EGFPhigh rEBs gave 
rise mainly to atrial myocytes (Figure 29), suggest that not only the maturity status of 
the cardiac cells differs from each other, but there may also be a subtype-specificity of 
the CAG-EGFP system involved. In this case CAG-EGFPhigh cells would identify 
NKX2.5low atrial progenitors, able to give rise to atrial myocytes and smooth muscle 
cells (Figure 26 and 27). This is in good accordance with the report of Nakano et al., 
demonstrating that a pool of cells of the second heart field located in the venous pole of 
the heart tube (from where the atria arise) give rise solely to atrial cardiomyocytes and 
smooth muscle cells during mouse embryogenesis140. These Isl1 and sarcolipin positive 
cells could be isolated and after 4 days of in vitro differentiation most of the colonies 
expressed low levels of Nkx2.5. 
It has also been shown in atrial Nkx2.5 conditional knockout mice that Nkx2.5 
serves as a negative regulator for proliferation of atrial myocytes141. Zebra fish studies 
also suggested a role for the Nkx2.5 transcription factor in limiting atrial cell number 
and promoting ventricular cell number, while loss of nkx2.5 function resulted in the 
opposite effect142. This study also demonstrated that nkx2.5 is responsible for sustaining 
ventricular myocyte attributes through repression of atrial chamber identity and that loss 
of Nkx gene function can cause ventricular myocytes to transform into atrial myocytes.  
 Human embryonic stem cells, unlike mouse ESCs, show low survival rate as 
single cells due to disruption of E-cadherin signalling caused by enzymatic 
dissociation143. The same is true for early derivatives of hESCs131, 144. In accordance 
with these findings, our experiments indicated that the CAG-EGFPhigh CPCs are not 
able to survive as single cells, at least not under suspension culture conditions (Figure 
32).  
 In order to enhance overall CM yield we had to enhance survival of CAG-
EGFPhigh cells after the sorting procedure. This could be performed by supporting the 
reaggregation of the isolated cells with Thiazovivin treatment or applying an END-2 
conditioned medium (Figure 32). Better reaggregation ability resulted in CAG-
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EGFPhigh rEBs with increased size (Figure 34), but with decreased cardiac mRNA 
levels (Figure 35). Long-term administration of Isoproterenol enhanced TNNT2 levels 
of CAG-EGFPhigh rEBs cultured in END2 conditioned medium, while the size of the 
rEBs were not affected (Figure 36). This optimized culture method generates CAG-
EGFPhigh rEBs with increased cell number, but similar troponin levels as that of rEBs 
cultured under basic conditions (Figure 24 and 35).  
 Neuregulin was suggested to enhance proliferation of CMs82, to increase CM 
yield from mESCs145-147 and to enhance the proportion of ventricular myocytes among 
the generated CMs (10% nodal versus 90% ventricular subtype)84. However, in our 
system, Neuregulin failed to enhance TNNT2 levels of the CAG-EGFPhigh rEBs, but this 
may reflect that Neuregulin-dependent regulation of subtype specification happens at 
earlier stages of differentiation.  
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7. Conclusions 
 
1. The CAG promoter-driven EGFP reporter system enables the selection of 
transgene-expressing hESCs. Moreover, cardiomyocytes differentiated from CAG-
EGFP expressing hESCs can be easily identified based on their extremely high EGFP 
expression due to the cardiac tissue-specific transcriptional upregulation of the CAG 
promoter. These two features of this CAG promoter variant led to the designation as a 
“double feature promoter”.   
2. Directed differentiation of human embryonic stem cells results in enrichment 
of CAG-EGFPhigh progenitors. 
3. The CAG-EGFP system offers the advantage to isolate NKX2.5low cardiac 
progenitor cells. During differentiation CAG-EGFPhigh cardiac progenitor cells 
upregulate cardiomyocyte markers, such as SIRPA, VCAM1 and ALCAM. 
4. Isolated CAG-EGFPhigh cardiac progenitors are able to maintain their cardiac 
commitment during differentiation when cultured as 3D aggregates in conventional 
differentiation medium. 
5. CAG-EGFPhigh progenitor cells can generate spontaneously contracting 3D 
aggregates. These rEBs contain more than 90% of mature cardiomyocytes and show 
enhanced NKX2.5 and MYL7 transcription. CAG-EGFPhigh cells possess a more 
restricted differentiation potential than previously described cardiovascular progenitor 
cells, since CAG-EGFPhigh cardiac progenitor cells give rise to smooth muscle cells and 
atrial myocytes, but fail to differentiate into endothelial cells under 3D culture 
conditions.  
6. Reaggregation and survival properties of CAG-EGFPhigh CPCs can be 
enhanced by Thiazovivin or by the use of an END-2 conditioned medium, resulting 
rEBs with larger size than under control conditions. In our hands the cardioinductive 
effect of END-2 was not detectable and Isoproterenol, a beta-adrenerg agonist was 
needed to support the cardiogenic potential of CAG-EGFPhigh CPCs when cultured in 
END-2 conditioned medium as 3D aggregates.     
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The application of this ‘‘double-feature’’ promoter provides a unique 
opportunity to examine the selective markers, including cell surface proteins of the 
cardiac lineage from early CPCs to late CMs and allows purification and enrichment of 
cardiac cells. 
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8. Summary 
 
The achievements displayed in the dissertation include characterization of a 
novel in vitro method for identification and isolation of human embryonic stem cell-
derived cardiomyocytes and cardiac progenitors, characterization of the cardiac 
progenitors identified by this method and introduction of an optimized culture condition 
for cardiac progenitors to enhance overall cardiomyocyte yield.  
The method utilizes the special, double-feature characteristics of the CAG 
promoter, driving the expression of the green fluorescent protein (GFP) in 
undiffereniated stem cells and providing exceptionally high GFP expression in hESC-
derived cardiomyocytes, while its activity in other cell types remains modest. This 
exceptionally high GFP signal is also characteristic for cardiac progenitors, allowing the 
isolation of progenitor cells, which are still capable to divide and differentiate into atrial 
type cardiomyocytes and, to a lesser extent, into smooth muscle cells. Cardiac 
commitment of the progenitors could be best maintained by supporting the initiation of 
direct cell-cell contacts through 3D culture. Enhanced survival of cardiac progenitors 
after isolation could be achieved, and by applying a specific combination of treatments 
cardiomyocyte yield could also be enhanced.  
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9. Összefoglalás 
 
A doktori disszertációban részletezett tudományos munka eredményeként 
megszületett egy olyan új módszer, amely humán embrionális őssejt eredetű 
szívizomsejtek és azok előalakjainak, az ún. szívizom progenitorsejteknek a 
felismerését és kiválogatását teszi lehetővé. A munka részét képezte az ilyen módon 
kiválogatható szívizom progenitorsejtek jellemzése, valamint egy olyan tenyésztési 
körülmény kidolgozása is, ami a progenitorsejtek osztódását és szívizom irányú 
elköteleződését egyaránt támogatja. 
A módszer a CAG promóter egy variánsának különleges, kétarcú tulajdonságán 
alapul, amely egyrészt “megszólaltatja” a zöld fluoreszcens fehérjét (GFP) 
differenciálatlan őssejtekben, másrészt különösen erős GFP kifejeződést bíztosít az 
őssejtekből keletkező szívizomsejtekben, míg más sejttípusok esetében aktivitása 
lényegesen gyengébb. Ez a különösen erős GFP jel a szívizom progenitorsejtekre is 
jellemző, így ezek a még osztódásra képes sejtek is kiválogathatók az őssejtek 
különböző típusú utódsejtjeit tartalmazó tenyészetekből. A kiválogatott 
progenitorsejtekből főleg pitvari típusú szívizomsejtek keletkeznek, de képesek 
simaizom típusú sejtek létrehozására is. A kiválogatott progenitorsejtek túlélését és 
szívizomirányú elköteleződését is elősegíti, ha sejt-sejt kapcsolatok kialakítására 
alkalmas 3D struktúrában tenyésznek, míg a megfelelő kezelések alkalmazásával az 
előállított szívizomsejtek mennyisége növelhető.  
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